<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001896.pub2" GROUP_ID="MENSTR" ID="934199081315331115" MERGED_FROM="" MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Short title (no longer in use): Dysmenorrhoea: Nerve Interruption: Pain&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: Update of Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea&lt;/p&gt;" NOTES_MODIFIED="2005-08-25 14:00:00 +0200" REVIEW_NO="521" REVMAN_SUB_VERSION="5.0.17 beta" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke">
<TITLE>Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea</TITLE>
<CONTACT MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="10564" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Michelle</FIRST_NAME><LAST_NAME>Proctor</LAST_NAME><POSITION>Editor, Cochrane Menstrual Disorders and Subfertility Group</POSITION><EMAIL_1>michelleproctor@clear.net.nz</EMAIL_1><EMAIL_2>michelle.proctor@corrections.govt.nz</EMAIL_2><URL>research/cochrane</URL><ADDRESS><DEPARTMENT>Psychological Service</DEPARTMENT><ORGANISATION>Department of Corrections</ORGANISATION><ADDRESS_1>PO Box 302457</ADDRESS_1><ADDRESS_2>North Harbour</ADDRESS_2><CITY>Auckland</CITY><ZIP>1310</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9448 3208</PHONE_1><FAX_1>+64 9 3035969</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="10564" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Michelle</FIRST_NAME><LAST_NAME>Proctor</LAST_NAME><POSITION>Editor, Cochrane Menstrual Disorders and Subfertility Group</POSITION><EMAIL_1>michelleproctor@clear.net.nz</EMAIL_1><EMAIL_2>michelle.proctor@corrections.govt.nz</EMAIL_2><URL>research/cochrane</URL><ADDRESS><DEPARTMENT>Psychological Service</DEPARTMENT><ORGANISATION>Department of Corrections</ORGANISATION><ADDRESS_1>PO Box 302457</ADDRESS_1><ADDRESS_2>North Harbour</ADDRESS_2><CITY>Auckland</CITY><ZIP>1310</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9448 3208</PHONE_1><FAX_1>+64 9 3035969</FAX_1></ADDRESS></PERSON><PERSON ID="17335" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pallavi</FIRST_NAME><LAST_NAME>Latthe</LAST_NAME><SUFFIX>MRCOG</SUFFIX><POSITION>Consultant</POSITION><EMAIL_1>Pallavi.Latthe@bwhct.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>Birmingham Women's Hospital</ORGANISATION><ADDRESS_1>Edgbaston</ADDRESS_1><CITY>Birmingham</CITY><ZIP>B15 2TG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 627 2672</PHONE_1><FAX_1>+44 121 627 2667</FAX_1></ADDRESS></PERSON><PERSON ID="9CE26E7F82E26AA200CD32E53036321F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cindy</FIRST_NAME><LAST_NAME>Farquhar</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>c.farquhar@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>FMHS Park Road</ADDRESS_1><ADDRESS_2>Grafton</ADDRESS_2><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 6309943</PHONE_1><FAX_1>+64 9 6309858</FAX_1></ADDRESS></PERSON><PERSON ID="7741" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Khalid</FIRST_NAME><LAST_NAME>Khan</LAST_NAME><POSITION>Consultant Obstetrician and Gynaecologist</POSITION><EMAIL_1>k.s.khan@bham.ac.uk</EMAIL_1><EMAIL_2>sandra.bullock@bwhct.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>Birmingham Women's Hospital</ORGANISATION><ADDRESS_1>Edgbaston</ADDRESS_1><CITY>Birmingham</CITY><ZIP>B15 2TG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 607 4712</PHONE_1><PHONE_2>+44 121 627 2667</PHONE_2></ADDRESS></PERSON><PERSON ID="9027" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Neil</FIRST_NAME><LAST_NAME>Johnson</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>n.johnson@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>PO Box 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 3737599 ext: 89488</PHONE_1><FAX_1>+64 9 3035969</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-12 02:34:12 +0100" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;New studies found and included or excluded: 6/9/04&lt;/p&gt;&lt;p&gt;Reformatted: 9/3/99&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="24" MONTH="8" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="6" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2007"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Update 2004: four new trials were added (Johnson 2004; Vercellini 2003; Yen 2001; Zullo 2003) and information on one trial updated (Sutton 2001). Vercellini 2003 replaced preliminary data from a 1997 abstract that was included in the original review.&lt;/p&gt;"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke"><DATE DAY="20" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:29:11 +0200" MODIFIED_BY="Jane Clarke">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Princess of Wales Memorial Trust administered by the Mercia Barnes Fund</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>LUNA trial grant CF 371 funded by WellBeing, Royal College of Obstetrics and Gynaecology (RCOG)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Not enough evidence to support the use of surgical nerve interruption for dysmenorrhoea</TITLE>
<SUMMARY_BODY>
<P>Dysmenorrhoea (painful menstrual cramps) is a common problem. The contraceptive pill and anti-inflammatory drugs (NSAIDs) are effective treatments in 80% of women with dysmenorrhoea but for others surgery is a considered option. Uterine nerve ablation (UNA) and presacral neurectomy (PSN) both involve surgical interruption of the sensory nerve fibres near the cervix to block the pain pathway. The review of trials found there was only limited evidence to support the use of surgery for primary dysmenorrhoea and little evidence for its use in women with endometriosis. No adverse effects were found with UNA but PSN was found to cause treatable constipation. More research is needed. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Dysmenorrhoea is the occurrence of painful menstrual cramps of uterine origin and is a very common gynaecological complaint with negative effect on a sufferer's quality of life. Medical therapy for dysmenorrhoea includes oral contraceptive pills (OCP) and nonsteroidal anti-inflammatory drugs (NSAIDs) which both act by suppressing prostaglandin levels. While these treatments are very successful there is still a 20 to 25% failure rate and surgery has been an option for such cases. Uterine nerve ablation (UNA) and presacral neurectomy (PSN) are two surgical treatments that have become increasingly utilised in recent years due to advances in laparoscopic procedures. These procedures both interrupt the majority of the cervical sensory pain nerve fibres. Observational studies have supported the use of these procedures for primary dysmenorrhoea. However, both operations only partially interrupt the cervical sensory nerve fibres in the pelvic area and, therefore, this type of surgery may not always benefit women with dysmenorrhoea. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness of surgical interruption of pelvic nerve pathways as treatment for primary and secondary dysmenorrhoea, and to determine the most effective surgical treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched 9 June 2004), CENTRAL (<I>The Cochrane Library</I> Issue 2, 2004), MEDLINE (1966 to Nov 2003), EMBASE (1980 to Nov 2003), and CINAHL (1982 to Oct 2003). Attempts were also made to identify trials from the metaRegister of Controlled Trials and the citation lists of review articles and included trials. In most cases the first or corresponding author of each included trial was contacted for additional information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>The inclusion criteria were randomised comparisons of surgical techniques of interruption of the pelvic nerve pathways (using both open and laparoscopic procedures) for the treatment of primary and secondary dysmenorrhoea. The main outcome measures were pain relief and adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Eleven randomised controlled trials (RCTs) were identified that initially appeared to fulfil the inclusion criteria for this review. Two trials were subsequently excluded (Garcia Leon 2003; Sutton 1991). Of the remaining nine trials, eight were included in the meta-analysis. The results of one trial were included in the text of the review for discussion because the data were not available in a form that allowed them to be combined in the meta-analysis. Five trials investigated laparoscopic uterine nerve ablation (LUNA), two trials laparoscopic presacral neurectomy (LPSN) and two open presacral neurectomy (PSN).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>For the treatment of primary dysmenorrhoea there was some evidence of the effectiveness of laparoscopic uterine nerve ablation (LUNA) when compared to a control or no treatment. The comparison between LUNA and laparoscopic presacral neurectomy (LPSN) for primary dysmenorrhoea showed no significant difference in pain relief in the short term; however, long-term LPSN was shown to be significantly more effective than LUNA. For the treatment of secondary dysmenorrhoea six identified RCTs addressed endometriosis and one included women with uterine myomas. The treatment of LUNA combined with surgical treatment of endometrial implants versus surgical treatment of endometriosis alone showed that the addition of LUNA did not aid pain relief. For PSN combined with endometriosis treatment versus endometriosis treatment alone there was an overall difference in pain relief although the data suggests this may be specific to laparoscopy and for midline abdominal pain only. Adverse events were significantly more common for presacral neurectomy; however, the majority were complications such as constipation, which may spontaneously improve.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is insufficient evidence to recommend the use of nerve interruption in the management of dysmenorrhoea, regardless of cause. Future methodologically sound and sufficiently powered RCTs should be undertaken.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Dysmenorrhoea is the occurrence of painful menstrual cramps of uterine origin. Dysmenorrhoea is a very common gynaecological complaint that can affect up to 50% of women (<LINK REF="REF-Sobczyk-1980" TYPE="REFERENCE">Sobczyk 1980</LINK>). As such, it has a significant impact not just on personal health but also economically, through lost working hours (<LINK REF="REF-Dawood-1988" TYPE="REFERENCE">Dawood 1988</LINK>). </P>
<P>Dysmenorrhoea is commonly defined as two subcategories. When the menstrual pelvic pain is associated with an identifiable pathological condition, such as endometriosis, adenomyosis or pelvic adhesions reflecting previous inflammation, it is considered to be secondary dysmenorrhoea. In contrast menstrual pain without organic pathology is considered to be primary dysmenorrhoea (<LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>). According to standard gynaecological texts primary dysmenorrhoea usually occurs at or shortly after (6 to 12 months) menarche, when ovulatory cycles are established. The pain duration is typically 48 to 72 hours and is associated with menstrual flow. In contrast, secondary dysmenorrhoea is more likely to occur years after the onset of menarche and premenstrually as well as during menstruation. In practice the accuracy of diagnosis depends on the availability and the use of diagnostic tools.</P>
<P>The aetiology of primary dysmenorrhoea has been the source of considerable debate. However, laboratory and clinical research have identified over-production of uterine prostaglandins as a substantial contributing factor to the painful cramps that are the major symptom of dysmenorrhoea (<LINK REF="REF-Rosenwaks-1980" TYPE="REFERENCE">Rosenwaks 1980</LINK>). Prostaglandins are also implicated in secondary dysmenorrhoea: however, anatomical mechanisms can also be identified, depending on the type of accompanying pelvic pathology (<LINK REF="REF-Dawood-1990" TYPE="REFERENCE">Dawood 1990</LINK>).</P>
<P>Medical therapy includes oral contraceptive pills (OCP) and nonsteroidal anti-inflammatory drugs (NSAIDs) which both act by suppressing prostaglandin levels (<LINK REF="REF-Furniss-1982" TYPE="REFERENCE">Furniss 1982</LINK>). Although the use of both OCPs and NSAIDs (<LINK REF="REF-Marjoribanks-2003" TYPE="REFERENCE">Marjoribanks 2003</LINK>; <LINK REF="REF-Proctor-2003" TYPE="REFERENCE">Proctor 2003</LINK>) has been very successful, there is still a 20 to 25% failure rate (<LINK REF="REF-Dawood-1985" TYPE="REFERENCE">Dawood 1985</LINK>; <LINK REF="REF-Henzl-1985" TYPE="REFERENCE">Henzl 1985</LINK>). Pelvic nerve surgery has been a treatment for cases of dysmenorrhoea that fail to respond to medical therapy.</P>
<P>The pelvic viscera (internal organs) receive nerve impulses from both sympathetic (thoracolumbar) and parasympathetic (craniosacral) nervous systems (<I>see</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The parasympathetic and sympathetic pelvic nerve pathways are associated with the spinal vertebrae, in particular the second to fourth sacral segments (S2 to 4) and the tenth thoracic (T10) to the first lumbar segment (L1). The corpus, cervix and proximal fallopian tubes transmit pain through sympathetic fibres that arise from T10 to L1. These fibres include neurons that are part of the uterosacral ligaments and eventually merge into the superior hypogastric plexus (presacral nerve). The presacral nerve does not receive fibres from the ovaries or lateral pelvic structures. The lateral pelvis transmits pain via nervi erigentes (pelvic splanchnic nerve) arising from S2 to 4. The presacral nerve divides into the hypogastric nerve that form the inferior hypogastric plexus, and this plexus divides into vesical, middle rectal and uterovaginal (Frankenhauser's) plexuses (<LINK REF="REF-Frankenhauser-1864" TYPE="REFERENCE">Frankenhauser 1864</LINK>). The transection of the uterosacral ligaments, and the network of nerves it contains, is a simple surgical procedure for treatment of pelvic pain. The original work by Doyle described vaginal and abdominal approaches to divide the attachments of the uterosacral ligaments to the cervix (<LINK REF="REF-Doyle-1955" TYPE="REFERENCE">Doyle 1955</LINK>). </P>
<P>When diagnostic laparoscopy is indicated, uterine nerve ablation (UNA) and presacral neurectomy (PSN) are two surgical treatments that have become increasingly utilised in recent years. UNA involves the transection of the uterosacral ligaments at their insertion into the cervix, whereas PSN involves the total removal of the presacral nerves lying within the boundaries of the interiliac triangle. These procedures both interrupt the majority of the cervical sensory nerve fibres thus diminishing uterine pain (<LINK REF="REF-Sutton-1993" TYPE="REFERENCE">Sutton 1993</LINK>). There is wide variation in the techniques and practice of laparoscopic UNA (<LINK REF="REF-Latthe-2004b" TYPE="REFERENCE">Latthe 2004b</LINK>) and it is considered to be a relatively straightforward procedure that is achievable by all competent gynaecologic laparoscopists. Observational studies have supported the use of laparoscopic UNA for both primary and secondary dysmenorrhoea with either complete relief or substantial reduction in menstrual pain in the majority of participants (<LINK REF="REF-Donnez-1989" TYPE="REFERENCE">Donnez 1989</LINK>; <LINK REF="REF-Ewen-1994" TYPE="REFERENCE">Ewen 1994</LINK>; <LINK REF="REF-Feste-1985" TYPE="REFERENCE">Feste 1985</LINK>; <LINK REF="REF-Gurgan-1992" TYPE="REFERENCE">Gurgan 1992</LINK>; <LINK REF="REF-Perez-1990" TYPE="REFERENCE">Perez 1990</LINK>; <LINK REF="REF-Sutton-1989" TYPE="REFERENCE">Sutton 1989</LINK>; <LINK REF="REF-Wiborny-1998" TYPE="REFERENCE">Wiborny 1998</LINK>). PSN involves the interruption of a greater number of nerve pathways than UNA: therefore, it is a more complex procedure, entails more operative risk and demands a high degree of skill by a surgeon who has specific training in this technique (<LINK REF="REF-Daniell-1995" TYPE="REFERENCE">Daniell 1995</LINK>). However, despite these drawbacks the use of PSN is also supported by observational studies showing similar results to that of UNA for both primary and secondary dysmenorrhoea (<LINK REF="REF-Chen-1997" TYPE="REFERENCE">Chen 1997</LINK>; <LINK REF="REF-Nezhat-1992" TYPE="REFERENCE">Nezhat 1992</LINK>). </P>
<P>There are, however, limitations to the usefulness of UNA and PSN. A long-term study showed that success rates declined rapidly over time, from 72% in the first year to 39% in the fourth for LUNA (<LINK REF="REF-Papasakelariou-1996" TYPE="REFERENCE">Papasakelariou 1996</LINK>). Other studies have shown risk of anatomical distortion such as uterine prolapse and bladder dysfunction (<LINK REF="REF-Davis-1996" TYPE="REFERENCE">Davis 1996</LINK>; <LINK REF="REF-Fitzpatrick-1995" TYPE="REFERENCE">Fitzpatrick 1995</LINK>). There is also the concern regarding the effects of interruption of the pelvic nerves to the uterine muscles in subsequent pregnancies, such as painless labour. In addition, both operations only partially interrupt some of the cervical sensory nerve fibres in the pelvic area; therefore, dysmenorrhoea associated with additional pelvic pathology may not always benefit from this type of surgery. For this reason these techniques are often combined with additional treatments such as vaporisation or excision of endometrial implants.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effectiveness of surgical interruption of pelvic nerve pathways (by both open and laparoscopic UNA or PSN) when compared to no treatment (where the control group receives either no treatment or a recognised treatment which is also performed in the intervention group) and to explore if the effects vary according to: (1) primary or secondary dysmenorrhoea and (2) UNA or PSN.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All prospective randomised controlled trials comparing surgical interruption of pelvic nerve pathways (by both open and laparoscopic UNA and PSN) to no treatment or other treatment, for women with primary or secondary dysmenorrhoea.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Inclusion criteria: <BR/>
</P>
<UL>
<LI>women of reproductive years;</LI>
<LI>women with primary dysmenorrhoea (no identifiable organic pathology);</LI>
<LI>women with secondary dysmenorrhoea (identifiable specific pathology).</LI>
</UL>
<P>
<BR/>Exclusion criteria: <BR/>
</P>
<UL>
<LI>women with secondary dysmenorrhoea associated with the use of intrauterine contraceptive devices.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Specific interventions that were considered.<BR/>
</P>
<UL>
<LI>UNA (laparoscopic or open) versus no treatment (as control) or other treatment for primary dysmenorrhoea.</LI>
<LI>PSN (laparoscopic or open) versus no treatment (as control) or other treatment for primary dysmenorrhoea.</LI>
<LI>UNA (laparoscopic or open) versus PSN (laparoscopic or open) for primary dysmenorrhoea.</LI>
<LI>UNA (laparoscopic or open) versus no treatment (where the control group was either no treatment or a recognised treatment which was also performed in the intervention group) or other treatment for secondary dysmenorrhoea.</LI>
<LI>PSN (laparoscopic or open) versus no treatment (where the control group was either no treatment or a recognised treatment which was also performed in the intervention group) or other treatment for secondary dysmenorrhoea.</LI>
<LI>UNA (laparoscopic or open) versus PSN (laparoscopic or open) for secondary dysmenorrhoea.</LI>
</UL>
<P>
<BR/>Laparoscopic and open techniques were combined for these interventions as there is some evidence to suggest they have similar ranges of pain relief for dysmenorrhoea (<LINK REF="REF-Nezhat-1992" TYPE="REFERENCE">Nezhat 1992</LINK>; <LINK REF="REF-Perez-1990" TYPE="REFERENCE">Perez 1990</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>(1) Pain relief <BR/>(a) Follow up more than six months after treatment<BR/>(b) Follow up - six months or less after treatment</P>
<P>Use of a visual analogue scale has been shown to be reliable in objective measurement of pain. Measurement with a VAS or other validated pain scales were studied and where these were not used other scales or dichotomous data were also considered. Changes in pain intensity were included.</P>
<P>(2) Adverse effects from the treatment (dichotomous data, number of participants with side effects)<BR/>(3) Quality of life
<BR/>

</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>All reports which described (or might have described) randomised controlled trials of surgical interruption of pelvic nerve pathways (both open and laparoscopic) in the treatment of dysmenorrhoea were obtained using the search strategy developed by the Cochrane Menstrual Disorders and Subfertility Group. </P>
<P>We searched:</P>
<P>(1) the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched 9 June 2004);</P>
<P>(2) the Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library</I> Issue 2, 2004;</P>
<P>(3) electronic databases MEDLINE (1966 to Nov 2003), EMBASE (1980 to Nov 2003), and CINAHL (1982 to Oct 2003) using OVID software.<BR/> <BR/>These databases were searched using the following keywords: <BR/>dysmenorrh$.tw<BR/>dysmenorrhea/<BR/>painful menstruat$.tw<BR/>pelvic pain/<BR/>surgery/<BR/>laparoscop$.tw<BR/>surgical procedures, laparoscopic<BR/>denervation<BR/>uterine nerve ablation.tw<BR/>presacral neurectomy.tw</P>
<P>(4) the metaRegister of Controlled Trials;</P>
<P>(5) citation lists of review articles and all included and excluded trials. </P>
<P>In most cases the first or corresponding author of included trials were contacted for additional information.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two authors of the review (MP and CF or MP and PL) performed the selection of trials for inclusion after employing the search strategy described previously.</P>
<P>Included trials were analysed for the following quality criteria and methodological details. This information is presented in the Table of included studies and helps provide a context for discussing the reliability of results. </P>
<P>
<B>
<I>Trial characteristics</I>
</B>
<BR/>(1) Method of randomisation<BR/>(2) Quality of allocation concealment until randomisation<BR/>(3) Presence or absence of blinding to treatment allocation after randomisation
<BR/>
(4) Number of women randomised, excluded or lost to follow up<BR/>(5) Whether an intention-to-treat analysis was done<BR/>(6) Whether a power calculation was done<BR/>(7) Duration, timing and location of the study<BR/>(8) Source of funding</P>
<P>
<B>
<I>Characteristics of the study participants</I>
</B>
<BR/>(1) Age and any other recorded characteristics of women in the study<BR/>(2) Other inclusion criteria<BR/>(3) Exclusion criteria<BR/>(4) Previously administered treatments</P>
<P>
<B>
<I>Interventions used</I>
</B>
<BR/>(1) Type of surgical treatment used (UNA or PSN; either laparoscopic or open) used<BR/>(2) Type of control, placebo or additional treatment used</P>
<P>
<B>
<I>Outcomes</I>
</B>
<BR/>(1) Methods used to measure pain relief achieved by treatment<BR/>(2) Methods used to measure adverse effects<BR/>(3) Methods used to measure quality of life</P>
<P>All assessments of the quality of trials and data extraction were performed independently by two authors of the review (MP and OS or MP and PL) using forms designed according to Cochrane guidelines. A third author (NJ) resolved any discrepancies. Additional information on trial methodology or actual original trial data were sought from the authors of trials which appeared to meet the eligibility criteria but had aspects of methodology that were unclear, or where the data were in a form unsuitable for meta-analysis. Authors from three trials were contacted to request additional information or data. Dr Vercellini supplied information about his study for the original review. Information and individual patient data were also supplied from the authors of <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>. John A Rock, a co-author from the <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK> trial also provided additional information on methodology and allocation. Authors for the <LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK> and <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK> trials were contacted but have not replied with additional information. </P>
<P>Statistical analyses were to be performed according to the statistical guidelines of the Cochrane Collaboration (<LINK REF="REF-Deeks-2004" TYPE="REFERENCE">Deeks 2004</LINK>). Difficulties were encountered with the reporting of pain relief as a continuous outcome. Meta-analysis with RevMan software offers a weighted mean difference (WMD) option to combine outcomes and requires data to be presented as absolute values of means with their standard deviations. </P>
<P>There is evidence to suggest that dichotomous outcomes can be derived from continuous data when interpreting pain relief data (<LINK REF="REF-Moore-1997" TYPE="REFERENCE">Moore 1997</LINK>). Therefore, attempts were made to dichotomise all other reported pain relief data in order to do subgroup analyses. Other pain scales were collapsed into dichotomous outcomes, pain relief or no pain relief. <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK> used a 5-point scale where 0 = no pain; 1 = mild pain requiring no medication; 2 = moderate pain responding to mild analgesia; 3 = severe pain necessitating potent pain relievers; 4 = incapacitating pain, unresponsive to potent pain relievers. This scale was dichotomised with pain scores of 0, 1, and 2 labelled as pain relief (baseline pain for all participants was a score of 3 or 4). <LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK> and <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK> had reported dichotomised data measured in a similar way in their articles, so their reported figures were used in the analysis. <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK> reported pain relief data as three subgroups midline, lateral and back pain; therefore, these data were described but not included in the meta-analysis. <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK> used a 0 to 10 scale for recording information on pain, 0 representing no pain and 10 the worst pain ever experienced. This scale was dichotomised with scores of 4 or less labelled as pain relief. Where data points for six months post-treatment were missing due to loss to follow up the last value recorded was carried forward (5 out of 26 women in the LUNA group and 5 of 23 in the control group). <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK> reported the number of women without dysmenorrhoea or dysmenorrhoea mild enough that no medication was required; these figures were combined and labelled as pain relief. Data from intention-to-treat analyses were used where available (for example <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>).</P>
<P>Heterogeneity between the results of different studies was examined by inspecting the scatter in the data points and the overlap in their confidence intervals and more formally by checking the results of the chi squared tests.<BR/>
<BR/>For the dichotomous data, results of each study were expressed as an odds ratio with 95% confidence intervals and combined for meta-analysis with RevMan software using the Peto-modified Mantel-Haenszel method. The outcome of pain relief is considered a positive consequence of treatment, therefore, a higher proportion of women with pain relief was considered a benefit (odds ratio (OR) greater than 1). The outcome of adverse effects is a negative consequence, therefore, higher numbers were considered to be detrimental (desirable, OR less than 1). This needs to be taken into consideration when the summary graphs are viewed. 
<BR/>

</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Eleven RCTs were identified involving surgical interruption of the pelvic nerve pathways as treatment for dysmenorrhoea.</P>
<P>
<B>Trials excluded from the review</B>
<BR/>Two trials were excluded from the review. One excluded trial (<LINK REF="STD-Sutton-1994" TYPE="STUDY">Sutton 1994</LINK>) compared laser laparoscopy (involving LUNA and surgical treatment of endometrial implants) to no treatment (expectant management only). Therefore due to the lack of a control group that had laser vaporisation only, the outcome data as a result of LUNA surgery could not be distinguished from the outcomes resulting from the laser vaporisation. The other excluded trial (<LINK REF="STD-Garcia-Leon-2003" TYPE="STUDY">Garcia Leon 2003</LINK>) compared LUNA and LPSN in women with chronic pelvic pain which may or may not have included dysmenorrhoea. Approximately 60 to 80% of women in each treatment group had dysmenorrhoea at baseline however, we were unable to separate out data for women with dysmenorrhoea at baseline to determine which women benefited from treatment.</P>
<P>
<B>Trials included in the review</B>
<BR/>Nine RCTs met the criteria for inclusion in the review. All the studies described clear inclusion and exclusion criteria (<I>see</I> Included studies table for more information). An ongoing randomised trial of LUNA for women with chronic pelvic pain without endometriosis was also identified (<LINK REF="STD-Birmingham-trial" TYPE="STUDY">Birmingham trial</LINK>; <LINK REF="REF-Latthe-2003" TYPE="REFERENCE">Latthe 2003</LINK>). Data from this trial will be included when it becomes available. Currently 421 women have been recruited into this trial (October 2004) (http://www.luna.bham.ac.uk/trial/clinicians/recruitment.htm). The expected finishing date for the trial is September 2005 and the expected reporting date is December 2006 (<LINK REF="REF-Latthe-2003" TYPE="REFERENCE">Latthe 2003</LINK>).<BR/>
<BR/>
<B>
<I>Interventions</I>
</B>
<BR/>Two trials (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>) compared laparoscopic uterine nerve ablation (LUNA) with diagnostic laparoscopy only for women with primary dysmenorrhoea. Three trials (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>) combined LUNA and laser treatment of endometriosis implants as surgical techniques and compared them with laser treatment only, for women with secondary dysmenorrhoea. One trial compared LUNA and laparoscopic bipolar coagulation of uterine vessels with laparoscopic bipolar coagulation of uterine vessels only in women with dysmenorrhoea secondary to uterine myomas (<LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>). Three trials compared presacral neurectomy (PSN) combined with surgical treatment of endometriosis versus surgical treatment of endometriosis only as a control for treatment of secondary dysmenorrhoea (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>). The final included trial compared LUNA and LPSN as treatments for primary dysmenorrhoea (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>). </P>
<P>The surgery involved was performed using standard techniques. In one trial of LUNA, with diagnostic laparoscopy as a control (<LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>), the participants in the experimental group had bilateral uterosacral ligament electrocautery at their insertion into the cervix. The ligaments were then cut through and an electrical current was reapplied to the depth of the incision. The generator used was set at 5.8 W. </P>
<P>The Vercellini trial (<LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>) also used mechanical instruments and electro-surgery. The full thickness of the uterosacral ligaments was coagulated with bipolar forceps. A segment 1 cm or greater in depth and length was excised with scissors close to the uterine junction. </P>
<P>The Guildford, UK trial (<LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>) performed uterine nerve ablation with a CO<SUB>2</SUB> laser using a triple-puncture technique.</P>
<P>In the New Zealand trial (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) bilateral uterosacral ligament electrocautery was applied (blend current at power 30 units) 0.5 cm from the ligamentous insertion into the cervix until tissue was blanched. Complete transection of the ligaments was then undertaken with laparoscopic scissors and bipolar electrocautery reapplied to the base of the incision to secure haemostasis. </P>
<P>In the Taipei, Taiwan trial ligaments were coagulated and dissected at their insertion into the cervix with unipolar or bipolar electrocoagulation (<LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>). After dissection, grasping forceps were used to connect coagulated areas in a U-like fashion along the base of the cervix and uterosacral ligaments were cut through with mechanical operating scissors. Current was then applied to the depth of this incision. </P>
<P>The Keelung, Taiwan trial (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>) compared LUNA and LPSN. The technique used for LUNA was comparable to that used by <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>, and LPSN involved laparoscopic surgery and total removal of the presacral nerves that lie within the boundaries of the interiliac triangle. This was performed using unipolar or bipolar electrocautery, or both, the excised nerve tissue being later confirmed histologically. </P>
<P>The Italian trial (<LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>) compared laparoscopic PSN with ablation or excision of visible endometriotic lesions versus ablation or excision of visible endometriotic lesions only. In women undergoing PSN the presacral area was exposed with blunt dissection and all underlying tissue layers down to the periosteum were cauterised. A semilunar piece of retroperitoneal tissue was dissected and sent for pathologic confirmation of nerve fibre presence.</P>
<P>The last two trials (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>) used PSN via laparotomy combined with resection of endometriosis implants for the experimental groups. </P>
<P>
<B>
<I>Participants</I>
</B>
<BR/>All the trials included women between the ages of 18 to 50 years of age and the majority of the studies' participants appeared to have sought medical assistance for dysmenorrhoea. None of the trials gave clear information on the source of the women or how they were recruited into the studies. Two of the studies (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>) looked exclusively at women with primary dysmenorrhoea, excluding all participants with any pelvic pathology with a diagnostic laparoscopy. One study included women with dysmenorrhoea related to uterine myoma (<LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>). One study included two patient groups: women with primary dysmenorrhoea and women with secondary dysmenorrhoea associated with endometriosis (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>). The other studies included women with secondary dysmenorrhoea associated with endometriosis. Two of the included studies involving women with endometriosis included those with an AFS classification of stage III to IV endometriosis (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>), one trial included women with only stage I to III (<LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>) and the other trials included all stages I to IV (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>).<BR/>
<B>
<I>
<BR/>Outcomes</I>
</B>
<BR/>The primary outcome in all nine trials was pain relief. This was measured and reported in a variety of ways. Three studies (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>; <LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>) used a 5-point pain scale; Chen and Yen converted scores into either success or failure in pain relief while Lichten reported each participant's raw scores. Visual analogue scales (VAS) were also used in some of the trials: however, the length of the scales varied. <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK> used a 10 cm VAS as well as a 10-point pain scale. <LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK> used a 10-point VAS (but only reported dichotomised data) and a multidimensional scale. This scale comprised three components: limitation of working ability, coexistence of systematic symptoms and need for analgesics. <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK> used a 10-point VAS and a dichotomous measure of pain relief. <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK> and <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK> used a 100mm VAS, and <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK> simply reported whether pain relief did or did not occur. </P>
<P>Side effects were reported by the majority of studies as the number of women who suffered any specific adverse events for example constipation.<BR/>

<BR/>
Outcomes were assessed at various time periods following surgery. In two trials (<LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>; <LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>) participants were assessed at six months, although Tjaden stated that participants were followed for a minimum of 42 months. One trial assessed participants at three and six months (<LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>). In two trials (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) participants were assessed at three and 12 months. Two trials (<LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>) assessed participants at six and 12 months, although Vercellini extended follow up of some women for up to 36 months. In the final two trials (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>) all participants were followed up for at least 12 months. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>
<I>
<BR/>Randomisation and allocation concealment</I>
</B>
<BR/>Three of the trials received a quality allocation score of A based on adequate concealment prior to allocation (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>). Two studies received an allocation score of C (<LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>; <LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>) due to the use of case numbers in the allocation process. Despite poor allocation concealment other aspects of the Lichten study were adequate, such as double blinding and very strict inclusion and exclusion criteria. Other trials received an allocation score of B as there was not enough information in the trial report to determine whether the randomisation sequence was adequately concealed until interventions were assigned.</P>
<P>All nine included trials randomised participants to treatment.</P>
<P>
<B>
<I>Blinding</I>
</B>
<BR/>Double blinding was used in six studies, with blinding of the patient and the investigator (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>; <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>; <LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>); one was single blind (<LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>); and for the other trials blinding was unclear.</P>
<P>
<B>
<I>Intention-to-treat analysis and power calculations</I>
</B>
<BR/>Two trials (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>) included an intention-to-treat (ITT) analysis.</P>
<P>A power calculation was performed in five studies (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>). <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK> also included a power calculation but the trial was stopped before the number of women needed was reached. The monitoring committee stopped the study after evaluation of data from the first 26 women as it was considered unethical to deprive women with midline dysmenorrhoea the relief afforded by presacral neurectomy. Only eight of the 26 participants were randomised, while the others chose their group; however the data for each method of allocation was reported separately, so for this review only the randomised data were included.</P>
<P>All the included studies assessed comparability of the treatment and control groups at baseline; no appreciable differences in age, parity, condition or pain scores were reported. </P>
<P>
<B>
<I>Follow up</I>
<BR/>
</B>Follow up and withdrawal rates varied among trials. Two trials reported no withdrawals or losses to follow up (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>). In five trials less than 15% of randomised participants withdrew or were lost to follow up (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>; <LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>). In one trial of 180 participants only 116 (64%) were analysed: 29 became pregnant, 14 used OCP, 15 (8%) were lost to follow up and six women withdrew for other reasons (<LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>). In another trial, 18 of 39 women (46%) were excluded from analysis due to pathology at follow up (<LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>There were two trials with open PSN; all other trials use laparoscopic techniques.
<BR/>

<BR/>
<B>UNA (laparoscopic or open) versus control</B>
<BR/>
<I>Primary dysmenorrhoea</I>
<BR/>There were two studies compared LUNA versus control for primary dysmenorrhoea (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK>). At six months or less follow up there was no significant difference in pain relief (2 RCTs; N = 68; OR 1.43, 95% CI 0.56 to 3.69). The Chi squared test for heterogeneity showed there was significant heterogeneity between these two trials (10.27, degrees of freedon (df) = 1, P value &lt; 0.001). This heterogeneity was also evident by the scatter in the data points on the meta-analysis. </P>
<P>However, longer term pain relief (assessed at 12 months) showed a significant difference between the experimental and control groups (2 RCTs; N = 68; OR 6.12, 95% CI 1.78 to 21.03). <BR/> <BR/>One trial (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) reported additional outcomes related to quality of life following treatment. Satisfaction rates at 12 months showed no difference between group (LUNA 15 of 18 satisfied; control 22 of 32; P value &gt; 0.05). Information on the need for further surgery (one hysterectomy in the LUNA group and two in the control group), and the need for additional treatment (three women in the no LUNA group were using OCP or Mirena), also indicated no difference between the two groups. </P>
<P>
<I>Secondary dysmenorrhoea</I>
<BR/>There were four trials that compared LUNA with surgical treatment of endometriosis versus surgical treatment of endometriosis only (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK>; <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>; <LINK REF="STD-Yen-2001" TYPE="STUDY">Yen 2001</LINK>). At six months or less follow up there was no significant difference in pain relief (3 RCTs; N= 190; OR 1.03, 95% CI 0.52 to 2.02). Longer term pain relief also showed no significant difference between groups (2 RCTs; N= 217; OR 0.77, 95% CI 0.43 to 1.39).<BR/>
<BR/>
<LINK REF="STD-Sutton-2001" TYPE="STUDY">Sutton 2001</LINK> reported comparable baseline pain scores, and at six months post-operative showed no significant difference between the experimental and control groups for dysmenorrhoea pain scores for the VAS scale (Mann-Whitney test, P value = 0.21 respectively). On the 10 cm VAS scale the experimental group pain scores at six months had a median of 4.8 (range 1 to 9.0), while the control pain scores had a median of 3.0 (range 0 to 9.8). </P>
<P>One trial reported data on pain relief up to 36 months following treatment (<LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>). There was no significant difference in pain relief between the treatment and control group following this extended follow up (1 RCT; N = 116; OR 0.84, 95% CI 0.39 to 1.80). </P>
<P>In one trial (<LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>) the 12 month Kaplan-Meyer cumulative probability of recurrence of moderate to severe dysmenorrhoea was 33.7% for the experimental group and 27.55% for the control group. An intention-to-treat analysis on participant satisfaction showed that 68% of the experimental group and 73% of the control group were very satisfied or satisfied with treatment; while 32% of the experimental group and 27% of the control group were uncertain, dissatisfied, or very dissatisfied with treatment. No adverse effects were reported for either group. <LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK> also collected additional quality of life data including the Short Form-36, Hospital Anxiety and Depression Scale, and the Revised Sabbatsberg Sexual Rating Scale. There were significant mean improvements in all scales; however, at one-year follow up the trial reported that there were no significant differences between groups.<BR/> <BR/>
<B>PSN (laparoscopic or open) versus control<BR/>
</B>
<I>Secondary dysmenorrhoea</I>
<B>
<BR/>
</B>Three trials compared PSN with surgical treatment of endometriosis versus surgical treatment of endometriosis only (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>; <LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>). Two trials used PSN (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>; <LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>) and one trial LPSN (<LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>). At six months or less follow up there was a significant difference in pain relief in favour of PSN (1 RCT; N = 126; OR 4.52, 95% CI 1.84 to 11.09). Pain relief measured up to 12 months following treatment also showed a significant difference between treatment groups (2 RCTs; N = 197; OR 3.14, 95% 1.59 to 6.21). In one trial (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>), which reported no difference in treatments, the authors originally collected information on the incidence, site and severity of pain and in analysis split their results into separate areas of pain. They interpreted their findings as showing a significant difference in the recurrence of midline abdominal dysmenorrhoeic pain, with the experimental group reporting what the authors interpreted as a significantly lower recurrence (P value = 0.06). There was a strong significant difference in the proportion of women with adverse effects from the treatment: the control group reported none but the PSN group reported 13 women with constipation, three with urinary urgency and two experienced a painless first stage of labour (OR 14.6, 95% CI 5.0 to 42.2). This trial also evaluated dysmenorrhoea on a multidimensional scoring system that included limitation of working ability, systemic symptoms, and need for analgesics. Using this scoring system there was no significant difference between the treatment and control groups with both groups showed a large reduction in symptoms (absent or mild symptoms - PSN 30 of 35 women, control 29 of 36 women)<BR/>
<BR/>
<LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK> also originally collected information on incidence and location of pain and split pain relief into areas of pain. They found that pain relief in the experimental and control groups were significantly different for midline abdominal pain (Fisher exact test, P value = 0.028). However, for back pain or lateral pain associated with dysmenorrhoea there were no significant differences between the groups. These results were based on only eight randomised participants.<BR/>
<BR/>
<B>UNA versus PSN (laparoscopic or open)<BR/>
</B>
<I>Primary dysmenorrhoea</I>
<BR/>There was only one study in this comparison and both types of surgery were performed laparoscopically (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>). Results of the meta-analysis showed that there was no significant difference between the two treatments at six months or less follow up (1 RCT; N = 68; OR 0.67, 95% CI 0.17 to 2.61). However at more than six months follow up the pain relief scores were significantly different with LPSN achieving more effective pain relief (1 RCT; N = 68; OR 0.10, 95% CI 0.03 to 0.32). There was also a strong significant difference in the number of adverse effects reported by the participants 94% of the LPSN group reported constipation with the LUNA group reporting none (1 RCT; OR 0.02, 95% CI 0.01 to 0.06).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This review assessed the effectiveness of surgical interruption of pelvic nerve pathways in the treatment of dysmenorrhoea. The techniques specifically investigated were uterine nerve ablation and presacral neurectomy (using both open and laparoscopic procedures). </P>
<P>The use of LUNA is shown by this review to be effective for primary dysmenorrhoea but in the long term (12 months) only. <LINK REF="STD-Lichten-1987" TYPE="STUDY">Lichten 1987</LINK> (N = 21) reported significant differences in pain scores between the experimental and control groups at both short-term and long-term follow up; however, a large trial (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>: primary dysmenorrhoea, N = 47) showed no difference in the short term (up to six months) yet a difference in favour of LUNA in the longer term. The results of the Lichten trial alone suggested that the effectiveness of LUNA may decline over time; however, results from the Johnson trial showed this was not the case. It should be noted that the Johnson trial had adequate allocation concealment and randomisation while the Lichten trial used sequential allocation. The drawback of short-term follow up is that the effect of treatment may overlap with the placebo effect of laparoscopy, thus the placebo effect could diminish differences between groups (<LINK REF="REF-Baker-1992" TYPE="REFERENCE">Baker 1992</LINK>). The results of <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>, which also investigated primary dysmenorrhoea, showed a clear decline in effectiveness. Chen reported a dramatic drop in the pain relief afforded by LUNA compared to LPSN at three and 12 months after surgery. These results are consistent with a previous long-term study which showed that success rates declined rapidly over time, from 72% in the first year to 39% in the fourth year (<LINK REF="REF-Papasakelariou-1996" TYPE="REFERENCE">Papasakelariou 1996</LINK>). In the long term, the lack of sustained benefit could be either due to regrowth of nerves or pain signals being transferred via alternative routes. Overall the meta-analysis suggested that the short-term results for LUNA are still uncertain. The results at 12 months showed that LUNA effectively reduced pain in primary dysmenorrhoea; however, the wide confidence intervals prompt caution in applying the results in practice. </P>
<P>For the comparison between LUNA and LPSN, the results of the meta-analysis showed that in the short term the two techniques were not significantly different in effectiveness; but long term, LPSN was significantly more effective in reducing pain (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>). One drawback of LPSN was the significantly higher level of adverse effects; constipation being the commonest, but urinary urgency and painless labour also being reported. Constipation is a manageable but inconvenient side effect and the authors suggested that it may spontaneously improve over time. </P>
<P>In the evaluation of the effectiveness of LUNA in treating secondary dysmenorrhoea, the meta-analysis shows no difference between LUNA compared to control at any time point. Vercellini 2003 continued to follow the majority of participants for 36 months and the lack of difference continued. The four studies indicated that UNA combined with surgical treatment of endometriosis was no more effective than surgical treatment of the endometriosis alone for treatment of secondary dysmenorrhoea. </P>
<P>The results for PSN as a treatment for secondary dysmenorrhoea associated with endometriosis were mixed. Overall the meta-analysis showed that PSN with conservative surgery for endometriosis was more effective than conservative surgery alone; however, results from individual trials varied. Candiani 1992 showed no significant difference between the experimental and control groups but midline abdominal dysmenorrhoeic pain was interpreted by the authors as responding better to PSN; however, the difference was not statistically significant (P value = 0.06). The Candiani trial included women with either a laparotomic or laparoscopic diagnosis of endometriosis and no information was reported on how the PSN procedure was performed. The other study, which was not included in the meta-analysis, reported a statistically significant difference in midline abdominal pain (P value = 0.03) but no difference in pain relief for women with lateral or back pain (<LINK REF="STD-Tjaden-1990" TYPE="STUDY">Tjaden 1990</LINK>). This trial included PSN via laparotomy only. A major shortcoming of both these trials was the small sample sizes. Candiani had a sample of 71 participants and, therefore, power to detect differences greater than 40% (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>). The difference in pain relief between the two groups was only 5%, therefore, no conclusions could be accurately drawn. The Tjaden study only randomised eight participants so the statistically significant result regarding midline pain was based on the results of the four participants in the experimental group. While the monitoring committee considered this to be a strong enough result to discontinue the trial it is not a large enough sample from which to claim effectiveness. The largest study in the meta-analysis (N = 126) (<LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>), which demonstrated that LPSN was effective as a treatment, was the only trial in which it was clear that all women had PSN via laparoscopy. This trial also excluded women without a midline component to their dysmenorrhoea; however, it should be noted that over 80% of women in this trial had a lateral component to their dysmenorrhoea. </P>
<P>Quality of life measures were reported in only one study (<LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK>) even though improvement of this is the ultimate goal for the patient and the clinician. </P>
<P>Overall, the small number of participants who have been entered into randomised controlled trials on UNA and PSN make it difficult to assess effectiveness in treating dysmenorrhoea. In the trials with null results inadequacy of power to detect a clinically important difference is an issue of concern. Overestimation of the expected clinical difference at the time of power calculation can lead to underestimation of the sample size. This seems to have happened in the Vercellini trial (<LINK REF="STD-Vercellini-2003" TYPE="STUDY">Vercellini 2003</LINK>) with the observed effect size showing wide confidence intervals (OR 1.13, 95% CI 0.56 to 2.28), indicating a potential for benefit as well as harm at the extremes of the confidence intervals. <LINK REF="STD-Candiani-1992" TYPE="STUDY">Candiani 1992</LINK> also reported wide confidence intervals after overestimating the clinical difference in treatments when calculating sample size (it had power to demonstrate a difference of 40%) (OR 1.61, 95% 0.51 to 5.13). The drawbacks of the Zullo study (<LINK REF="STD-Zullo-2003" TYPE="STUDY">Zullo 2003</LINK>) were single (fixed) block randomisation, lack of intention-to-treat analysis and limited generalisability of results due to a single centre trial (<LINK REF="REF-Latthe-2004a" TYPE="REFERENCE">Latthe 2004a</LINK>). </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Laparoscopic presacral neurectomy (PSN) is a surgical procedure that requires a high degree of skill by an experienced pelvic laparoscopic surgeon who is trained specifically in this retroperitineal operation. The presacral region may be highly vascular and the procedure carries major potential hazards for the unwary or inadequately trained surgeon. Conversely, although laparoscopic uterine nerve ablation (UNA) must be performed precisely to avoid complications it should be within the scope of all competent pelvic laparoscopic surgeons. </P>
<P>There is some evidence for continuing to investigate the use of laparoscopic PSN and UNA in primary dysmenorrhoea within clinical trials. There is currently no evidence to recommend the use of UNA to treat endometriosis although there is some evidence for the use of PSN. <BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>To help resolve the issue of effectiveness of neuroablation, clinicians may initiate good quality and adequately powered trials or participate in ongoing multicentre trials. There is a lack of good quality RCTs in all the comparisons examined in this review. The main issues are sample size and trial methodology. Trial design should include the following aspects to ensure adequate methodological quality: double blinding; secure concealed randomisation and allocation of participants; longer-term follow up (at least one year); placebo arms; valid and reliable measurement of outcomes (such as the VAS scale for pain and quality of life measures); use of a power calculation to ensure enough participants are included and followed up. Inclusion criteria should also include a full description of any pathology. An individual patient data meta-analysis may address the uncertainty by combining raw data from various studies included in this review as well as the data from ongoing studies (<LINK REF="STD-Birmingham-trial" TYPE="STUDY">Birmingham trial</LINK>; <LINK REF="STD-Birmingham-trial" TYPE="STUDY">Birmingham trial</LINK>; <LINK REF="REF-Latthe-2003" TYPE="REFERENCE">Latthe 2003</LINK>).<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to acknowledge the referees of the previous versions of this review for their helpful comments and the authors, of the included trials, that have supplied extra information or data. We would also like to acknowledge Owen Sinclair who, in the original review; performed the independent data extraction and quality assessment of six included trials, and Kathryn Burns who, in this update, added information from new trials into the appropriate tables.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr C Farquhar and Dr N Johnson are investigators in a randomised controlled trial of laparoscopic uterine nerve ablation (LUNA), which was funded by a grant from the Princess of Wales Memorial Trust and administered by the Mercia Barnes Fund of the Royal Australian and New Zealand College of Obstetrics and Gynaecology (RANZCOG) (NZ branch) (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>). Dr P Latthe is the Clinical Research Fellow and Mr KS Khan is the principal investigator on a LUNA trial funded by WellBeing, Royal College of Obstetrics and Gynaecology (RCOG), UK (CF/371) (<LINK REF="REF-Latthe-2003" TYPE="REFERENCE">Latthe 2003</LINK>).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Michelle Proctor: took the lead in writing the protocol and review, searched for trials, selected studies for inclusion and exclusion, performed independent data extraction and quality assessment of the included trials, and was responsible for statistical analysis and interpretation of the data.<BR/>Pallavi Latthe: selected studies for inclusion and exclusion, performed independent data extraction and quality assessment of the included trials for the 2004 update of the review and commented on drafts of the review.<BR/>Cindy Farquhar: initiated and conceptualised the review, and commented on drafts of the protocol and review.<BR/>Khalid S. Khan: supervised P. Latthe and commented on drafts of the review.<BR/>Neil Johnson: revised drafts of the protocol and review, and contributed to interpretation of the data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Candiani-1992" NAME="Candiani 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Candiani GB, Fedele L, Vercellini P, Bianchi S, Di Nola G. Presacral neurectomy for the treatment of pelvic pain associated with endometriosis: a controlled study. Am J Obstet Gynecol 1992;167(1):100-103.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Candiani GB, Fedele L, Vercellini P, Bianchi S, Di Nola G</AU>
<TI>Presacral neurectomy for the treatment of pelvic pain associated with endometriosis: a controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>167</VL>
<NO>1</NO>
<PG>100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1996" NAME="Chen 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Chen FP, Chang SD, Chu KK, Soong YK. Comparison of laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation for primary dysmenorrhea. J Reprod Med Obstet Gynecol 1996; 41(7);463-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen FP, Chang SD, Chu KK, Soong YK</AU>
<TI>Comparison of laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation for primary dysmenorrhea</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>7</NO>
<PG>463-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" NAME="Johnson 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Johnson NP, Farquhar CM, Crossley S, Yu Y, van Peperstraten AM, Sprecher M, Suckling J</AU>
<TI>A double-blind randomised controlled trial of laparoscopic uterine nerve ablation (LUNA) for women with chronic pelvic pain</TI>
<SO>(unpublished manuscipt)</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lichten-1987" NAME="Lichten 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Lichten EM, Bombard J. Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation. J Reprod Med 1987;32:37-41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lichten EM, Bombard J</AU>
<TI>Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-2001" NAME="Sutton 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sutton C, Pooley AS, Jones KD, Dover RW, Haines P</AU>
<TI>A prospective, randomized, double-blind controlled trial of laparoscopic uterine nerve ablation in the treatment of pelvic pain associated with endometriosis</TI>
<SO>Gynaecological Endoscopy</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>4</NO>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tjaden-1990" NAME="Tjaden 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Tjaden B, Schlaff WD, Kimball A, Rock JA. The efficacy of presacral neurectomy for the relief of midline dysmenorrhoea. Obstet Gynecol 1990; 76:89-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tjaden B, Schlaff WD, Kimball A, Rock JA</AU>
<TI>The efficacy of presacral neurectomy for the relief of midline dysmenorrhoea</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>76</VL>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vercellini-2003" NAME="Vercellini 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Vercellini P, Aimi G, Busacca M, Uglietti A, Viganali M, Crosignani PG. Laparoscopic uterosacral ligament resection for dysmenorrhea associated with endometriosis: Results of a randomized controlled trial. Fert Steril 1997; Oct Suppl:S3 (abstract).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vercellini P, Aimi G, Busacca M, Uglietti A, Viganali M, Crosignani PG</AU>
<TI>Laparoscopic uterosacral ligament resection for dysmenorrhea associated with endometriosis: Results of a randomized controlled trial (abstract)</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>October</VL>
<NO>Suppl</NO>
<PG>S3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG</AU>
<TI>Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: A pilot study</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>80</VL>
<NO>2</NO>
<PG>305-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yen-2001" NAME="Yen 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yen YK, Liu WM, Yuan CC, Ng HT</AU>
<TI>Addition of laparoscopic uterine nerve ablation to laparoscopic bipolar coagulation of uterine vessels for women with uterine myomas and dysmenorrhea</TI>
<SO>Journal of the American Association of Gynecologic Laparoscopists</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>4</NO>
<PG>573-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zullo-2003" NAME="Zullo 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zullo F, Palomba S, Zupi E, Russo T, Morelli M, Cappiello F, Mastrantonio P</AU>
<TI>Effectiveness of presacral neurectomy in women with severe dysmenorrhea caused by endometriosis who were treated with laparoscopic conservative surgery: a 1-year prospective randomized double-blind controlled trial</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>1</NO>
<PG>5-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-Leon-2003" NAME="Garcia Leon 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia Leon F, Oviedo Ortega G, Reyes Cuervo H, Ibarrola Buenabad E, Von der Meden W</AU>
<TI>Presacral neurectomy and uterine nerve ablation in chronic pelvic pain. Laparoscopic management. A comparative study</TI>
<SO>Ginecologia y Obstetricia De Mexico</SO>
<YR>2003</YR>
<VL>71</VL>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-1994" NAME="Sutton 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Sutton CJ, Ewen S, Whitelaw N, Haines P, Pooley A. Prospective randomized controlled trial of laser laparoscopy against placebo in stages I-III endometriosis: one year follow-up data. 27th British Congress of Obstetrics and Gynaecology 1995:no.176.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sutton CJ, Ewen S, Whitelaw N, Haines P, Pooley A</AU>
<TI>Prospective randomized controlled trial of laser laparoscopy against placebo in stages I-III endometriosis: one year follow-up data</TI>
<SO>27th British Congress of Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<PG>176</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Sutton CJ, Ewn SP, Whitelaw N, Haines P. Prospective, randomized double-blind controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild and moderate endometriosis. Fertility &amp;amp; Sterility 1994;62(4):696-700.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton CJ, Ewen SP, Whitelaw N, Haines P</AU>
<TI>Prospective, randomized double-blind controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild and moderate endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1994</YR>
<VL>62</VL>
<NO>4</NO>
<PG>696-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomised controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertility and Sterility 1997;68(6):1070-1074.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton CJ, Pooley AS, Ewen SP, Haines P</AU>
<TI>Follow-up report on a randomised controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>68</VL>
<NO>6</NO>
<PG>1070-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Birmingham-trial" NAME="Birmingham trial" YEAR="2003">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Baker-1992" NAME="Baker 1992" TYPE="JOURNAL_ARTICLE">
<AU>Baker PN, Symonds EM</AU>
<TI>The resolution of chronic pelvic pain after normal laparoscopy findings</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>835-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1997" NAME="Chen 1997" NOTES="&lt;p&gt;Chen FP, Soong YK. The efficacy and complications of laparoscopic presacral neurectomy in pelvic pain. Obstet Gynecol 1997;90(6):974-975.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chen FP, Soong YK</AU>
<TI>The efficacy and complications of laparoscopic presacral neurectomy in pelvic pain</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>6</NO>
<PG>974-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daniell-1995" NAME="Daniell 1995" NOTES="&lt;p&gt;Daniell JF, Lalonde CJ. Advanced laparoscopic procedures for pelvic pain and dysmenorrhoea. Bailliere's Clin Obstet Gynaecol 1995;9(4):795-807.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Daniell JF, Lalonde CJ</AU>
<TI>Advanced laparoscopic procedures for pelvic pain and dysmenorrhoea</TI>
<SO>Balliere's Clinical Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>4</NO>
<PG>795-807</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1996" NAME="Davis 1996" NOTES="&lt;p&gt;Davis GD. Uterine prolapse after laparoscopic uterosacral transection in nulliparous airborne trainees: A report of three cases. J Reprod Med 1996;41(4):279-82.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Davis GD</AU>
<TI>Uterine prolapse after laparoscopic uterosacral transection in nulliparous airborne trainees: A report of three cases</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>4</NO>
<PG>279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1985" NAME="Dawood 1985" NOTES="&lt;p&gt;Dawood MY. Dysmenorrhea. Pain Analges 1985;1:20.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY</AU>
<TI>Dysmenorrhea</TI>
<SO>Pain and Analgesia</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1988" NAME="Dawood 1988" NOTES="&lt;p&gt;Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes towards dysmenorrhea. Am J Med 1988;84(5A):23-29.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY</AU>
<TI>Nonsteroidal anti-inflammatory drugs and changing attitudes towards dysmenorrhea</TI>
<SO>American Journal of Medicine</SO>
<YR>1988</YR>
<VL>84</VL>
<NO>5A</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1990" NAME="Dawood 1990" NOTES="&lt;p&gt;Dawood MY. Dysmenorrhea. Clin Obstet Gynecol 1990;33(1):168-178.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY</AU>
<TI>Dysmenorrhea</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>33</VL>
<NO>1</NO>
<PG>168-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2004" NAME="Deeks 2004" NOTES="&lt;p&gt;, editors. . &lt;/p&gt;&lt;p&gt;Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. In: . Cochrane Reviewers&amp;#8217; Handbook 4.2.2 [updated December 2003]; Section 8. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;&lt;p&gt;Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. In: Alderson P, Green S, Higgins J, editors. Cochrane Reviewers&amp;#8217; Handbook 4.2.2 [updated December 2003]; Section 8. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="OTHER">
<AU>Deeks JJ, Higgins, JPT, Altman DG</AU>
<TI>Analysing and presenting results. In: Alderson P, Green S, Higgins J (Eds). Cochrane Reviewers&#8217; Handbook 4.2.2 [updated December 2003]; Section 8</TI>
<SO>The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donnez-1989" NAME="Donnez 1989" TYPE="JOURNAL_ARTICLE">
<AU>Donnez J, Nisolle E</AU>
<TI>CO2 laser laparoscopic surgery</TI>
<SO>Bailliere's Clinical Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>545-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doyle-1955" NAME="Doyle 1955" TYPE="JOURNAL_ARTICLE">
<AU>Doyle JB</AU>
<TI>Paracervical uterine denervation by transection of the cervical plexus for the relief of dysmenorrhoea</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1955</YR>
<VL>70</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ewen-1994" NAME="Ewen 1994" NOTES="&lt;p&gt;Ewen SP, Sutton CJG.  A combined approach to painful heavy periods: Laparoscopic laser uterine nerve ablation and endometrial resection. Gynaecol Endosc 1994;3(3):167-68.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ewen SP, Sutton CJG</AU>
<TI>A combined approach to painful heavy periods: Laparoscopic laser uterine nerve ablation and endometrial resection</TI>
<SO>Gynaecological Endoscopy</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>3</NO>
<PG>167-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feste-1985" NAME="Feste 1985" TYPE="JOURNAL_ARTICLE">
<AU>Feste JR</AU>
<TI>Laser laparoscopy: A new modality</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1985</YR>
<VL>30</VL>
<PG>413-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzpatrick-1995" NAME="Fitzpatrick 1995" NOTES="&lt;p&gt;Fitzpatrick CC, Flood H, Punch M, Hilgers TW, Elkins TE, McGuire EJ. Bladder dysfunction after repeat laparoscopic uterine nerve ablation (LUNA). Int Urogynecol J 1995;6(1):31-33.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fitzpatrick CC, Flood H, Punch M, Hilgers TW, Elkins TE, McGuire EJ</AU>
<TI>Bladder dysfunction after repeat laparoscopic uterine nerve ablation (LUNA)</TI>
<SO>International Urogynecological Journal</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>1</NO>
<PG>31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frankenhauser-1864" NAME="Frankenhauser 1864" TYPE="JOURNAL_ARTICLE">
<AU>Frankenhauser G</AU>
<SO>Die Bewegungenerven der Gebarmutter</SO>
<YR>1864</YR>
<VL>1</VL>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furniss-1982" NAME="Furniss 1982" NOTES="&lt;p&gt;Furniss LD. Nonsteroidal anti-inflammatory agents in the treatment of primary dysmenorrhea. Clin Pharm 1982;1:327-33.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Furniss LD</AU>
<TI>Nonsteroidal anti-inflammatory agents in the treatment of primary dysmenorrhea</TI>
<SO>Clinical Pharmacology</SO>
<YR>1982</YR>
<VL>1</VL>
<PG>327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gurgan-1992" NAME="Gurgan 1992" TYPE="JOURNAL_ARTICLE">
<AU>Gurgan T, Develioglu O, Bulent U, Hulusi Z, Aksu T, Kisnisci HA</AU>
<TI>Laparoscopic CO2 laser uterine nerve ablation for treatment of drug resisistant primary dysmenorrhoea</TI>
<SO>Fertility and Sterility</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>422-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henzl-1985" NAME="Henzl 1985" NOTES="&lt;p&gt;Henzl MR. Dysmenorrhea: Achievements and challenge. Sex Med Today 1985;9:8-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Henzl MR</AU>
<TI>Dysmenorrhea: Achievements and challenge</TI>
<SO>Sexual Medicine Today</SO>
<YR>1985</YR>
<VL>9</VL>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Latthe-2003" NAME="Latthe 2003" TYPE="OTHER">
<AU>Latthe P, Khan KS, Gupta JK, Daniels J, Hills RK, Gray R et al</AU>
<TI>A randomised controlled trial to assess the efficacy of laparoscopic uterosacral nerve ablation (LUNA) in the treatment of chronic pelvic pain: The trial protocol</TI>
<SO>Biomed Central Women's Health</SO>
<YR>2003</YR>
<VL>8 Dec</VL>
<PG>3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="(ISRCTN41196151)"/>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN: 1472-6874"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Latthe-2004a" NAME="Latthe 2004a" TYPE="OTHER">
<AU>Latthe P, Khan K; Commentary on Zullo F, Palomba S, Zupi E, Russo T, Morelli M, Cappiello F et al</AU>
<TI>Presacral neurectomy in addition to surgery for endometriosis increased the cure of severe dysmenorrhea</TI>
<SO>Evidence-based Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>1</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Latthe-2004b" NAME="Latthe 2004b" NOTES="&lt;p&gt;Latthe PM. Powell RJ. Daniels J. Hills RK. Gray R. Gupta JK. Khan KS. Variation in practice of laparoscopic uterosacral nerve ablation: a European survey. [Journal Article] Journal of Obstetrics &amp;amp; Gynaecology. 24(5):547-51, 2004 Aug.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Latthe PM, Powell RJ, Daniels J, Hills RK, Gray R, Gupta JK et al</AU>
<TI>Variation in practice of laparoscopic uterosacral nerve ablation: A European survey</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>547-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lichten-1987" NAME="Lichten 1987" NOTES="&lt;p&gt;Lichten EM, Bombard J. Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation. J Reprod Med 1987;32:37-41.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lichten EM, Bombard J</AU>
<TI>Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marjoribanks-2003" NAME="Marjoribanks 2003" TYPE="COCHRANE_REVIEW">
<AU>Marjoribanks J, Procotor ML, Farquhar C</AU>
<TI>Non-steroidal anti-inflammatory drugs for primary dysmenorrhoea (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997" NAME="Moore 1997" NOTES="&lt;p&gt;Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: verification from independent data. Pain 1997;69:127-130.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: verification from independent data</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nezhat-1992" NAME="Nezhat 1992" NOTES="&lt;p&gt;Nezhat C, Nezhat F. A simplified method of laparoscopic presacral neurectomy for the treatment of central pelvic pain due to endometriosis. Br J Obstet Gynaecol 1992;99(8):659-663.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Nezhat C, Nezhat F</AU>
<TI>A simplified method of laparoscopic presacral neurectomy for the treatment of central pelvic pain due to endometriosis</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<NO>8</NO>
<PG>659-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papasakelariou-1996" NAME="Papasakelariou 1996" NOTES="&lt;p&gt;Papasakelariou C. Long-term results of laparoscopic uterosacral nerve ablation. Gynaecol Endosc 1996;5:177-179.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Papasakelariou C</AU>
<TI>Long-term results of laparoscopic uterosacral nerve ablation</TI>
<SO>Gynaecological Endoscopy</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez-1990" NAME="Perez 1990" NOTES="&lt;p&gt;Perez JJ. Laparoscopic presacral neurectomy. Results of the first 25 cases. J Reprod Med 1990;35(6): 625-630.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Perez JJ</AU>
<TI>Laparoscopic presacral neurectomy. Results of the first 25 cases</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1990</YR>
<VL>35</VL>
<NO>6</NO>
<PG>625-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Proctor-2003" NAME="Proctor 2003" TYPE="COCHRANE_REVIEW">
<AU>Proctor ML, Roberts H, Farquhar C</AU>
<TI>Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenwaks-1980" NAME="Rosenwaks 1980" NOTES="&lt;p&gt;Rosenwaks Z, Seegar-Jones G.  Menstrual pain: its origin and pathogensis. J Reprod Med 1980;25(4 Suppl):207-212.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rosenwaks Z, Seegar-Jones G</AU>
<TI>Menstrual pain: its origin and pathogensis</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1980</YR>
<VL>25</VL>
<NO>Suppl 4</NO>
<PG>207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobczyk-1980" NAME="Sobczyk 1980" NOTES="&lt;p&gt;Sobczyk R.  Dysmenorrhea: The neglected syndrome. J Reprod Med 1980;25:200.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Sobczyk R</AU>
<TI>Dysmenorrhea: The neglected syndrome</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1980</YR>
<VL>25</VL>
<PG>200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutton-1989" NAME="Sutton 1989" TYPE="BOOK_SECTION">
<AU>Sutton CJG</AU>
<TI>Laser uterine nerve ablation</TI>
<SO>An atlas of laser operative laparoscopy and hysteroscopy</SO>
<YR>1989</YR>
<PG>43-52</PG>
<ED>Donnez J</ED>
<PB>Nauwelaerts</PB>
<CY>Leuven</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutton-1993" NAME="Sutton 1993" NOTES="&lt;p&gt;Sutton C, Whitelaw N. Laparoscopic uterine nerve ablation for intractable dysmenorrhoea. In Sutton C, Diamond M (eds.) Endoscopic Surgery for Gynecologists. London: WB Saunders 1993;39-65.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Sutton C, Whitelaw N</AU>
<TI>Laparoscopic uterine nerve ablation for intractable dysmenorrhoea</TI>
<SO>Endoscopic Surgery for Gynecologists</SO>
<YR>1993</YR>
<PG>39-65</PG>
<ED>Sutton C, Diamond M</ED>
<PB>WB Saunders</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiborny-1998" NAME="Wiborny 1998" NOTES="&lt;p&gt;Wiborny R, Pichler B.  Endoscopic dissection of the uterosacral ligaments for the treatment of chronic pelvic pain. Gynaecol Endosc 1998;7(1):33-35.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wiborny R, Pichler B</AU>
<TI>Endoscopic dissection of the uterosacral ligaments for the treatment of chronic pelvic pain</TI>
<SO>Gynaecological Endoscopy</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>1</NO>
<PG>33-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Johnson-2000" NAME="Johnson 2000" NOTES="&lt;p&gt;&amp;quot;. .&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Johnson N, Proctor M, Farquhar C</AU>
<TI>Surgical pelvic neuroablation for chronic pelvic pain: A systematic review</TI>
<SO>Gynaecological Endoscopy</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>6</NO>
<PG>351-61</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Candiani-1992">
<CHAR_METHODS>
<P>Allocation Concealment: unclear.<BR/>Randomisation: randomisation list, no other details reported.<BR/>Blinding: unclear.<BR/>Power Calculation: sample size based on assumption that dysmenorrhoea would resolve in 50% controls and 80 - 90% PSN group. Number of included patients gives 80% power for a difference of 30% 90% power for a difference of 40%, 0.05 level of significance.<BR/>Duration of trial: Recruitment from June 1986 to Jan 1990. Follow up of all women for at least one year.</P>
<P/>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 78.<BR/>Number of women analysed: 71.<BR/>Drop-outs/withdrawals: 7 women did not accept randomisation.<BR/>Inclusion criteria: women with endometriosis stage III or IV undergoing conservative surgery, moderate or severe midline or midline and lateral menstrual pelvic pain (dysmenorrhoea).<BR/>Diagnosis: gastro, urologic and orthopaedic evaluation to exclude other causes of pelvic pain, endometriosis confirmed at surgery.<BR/>Age: Control group mean 31.1, SD 3.6; PSN surgery group mean 32.5, SD 4.2.<BR/>Location: Milan, Italy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: presacral neurectomy with conservative surgery for endometriosis.<BR/>Control: conservative surgery for endometriosis.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dysmenorrhoea, measured by a 0 -10 analog scale and by a multidimensional scale which included limitation of working ability, systemic symptoms, and need for analgesics. Data reported as mild, moderate or severe pain prior to surgery and 12 months following surgery.<BR/>Adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chen-1996">
<CHAR_METHODS>
<P>Allocation Concealment: unclear.<BR/>Randomisation: unclear, stated as randomised no further details given.<BR/>Blinding: unclear.<BR/>Power Calculation: none stated.<BR/>Duration of trial: Recruited from Jan 1992 to July 1993. Patients followed up for 12 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 68.<BR/>Number of women analysed: 68.<BR/>Drop-outs/withdrawals: none.<BR/>Inclusion criteria: women with primary dysmenorrhoea and/or chronic pelvic pain.<BR/>Exclusion criteria: pelvic pathology (lesions).<BR/>Diagnosis: at laparoscopy, those without lesions that could be assoc with dysmenorrhoea were randomised.<BR/>Age: 18 to 40 years.<BR/>Location: Taiwan.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: laparoscopic uterine nerve ablation.<BR/>Control: laparoscopic presacral neurectomy.</P>
<P/>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain relief measured on a 5 point scale (0 = no pain to 4 = incapacitating pain unresponsive to potent pain relievers and the inability to function). Pain was measured at baseline, 3 months, 12 months and data was dichotomised into success 100 &gt; 50% pain relief or failure 50 &gt; 0% pain relief.<BR/>Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johnson-2004">
<CHAR_METHODS>
<P>Allocation concealment: stated as maintained securely by storage in sealed, sequentially-numbered opaque envelopes until the interventions were assigned during the laparoscopic procedure<BR/>Randomisation: computer-generated random number sequences <BR/>Blinding: used; participant and investigator blinded throughout the study<BR/>Power Calculation: for women with chronic pelvic pain in the absence of endometriosis, in order to have 80% power at the 95% confidence level to detect benefit in 50% of women, assuming 'benefit' in 10% controls, at least 48 participants would be required for analysis following randomisation. For women with endometriosis, in order to have 80% power at 95% confidence level to detect benefit in 90%, assuming benefit in 60% controls undergoing conventional endometriosis surgery, at least 76 participants would be required for analysis following randomisation. Allowing for losses to follow up, it was planned to recruit 50 women with chronic pelvic pain in the absence of endometriosis (achieved) and 80 women with endometriosis (not achieved). <BR/>Duration of trial: April 1997 to Dec. 2001. <BR/>Follow up: 24 hours, 3 and 12 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 123 (108 with dysmenorrhoea)<BR/>Number of women analysed: 123 <BR/>Drop-outs/withdrawals: 14 were excluded based on laparoscopic findings <BR/>Loss to follow up:<BR/>24 hours: 1<BR/>3 months: 3 (2 LUNA and 0 no LUNA in the population with no endometriosis; 0 LUNA and 1 no LUNA in the endometriosis population). <BR/>12 months: 17 (4 LUNA and 2 no LUNA in the population with no endometriosis; 6 LUNA and 5 no LUNA in the endometriosis population)<BR/>Inclusion criteria: Women aged 18 to 45 years inclusive; a history of chronic pelvic pain (either dysmenorrhoea, non-menstrual pelvic pain, defaecatory pain or deep dyspareunia for more than 6 months); no change in medication for the 3 months prior to trial recruitment. Exclusion criteria: previous hysterectomy or pelvic malignancy; previous LUNA; known ovarian cysts; plan for a pregnancy within 12 months; intention to change other medical treatment which could influence pelvic pain scores within 12 months; laparoscopic findings rendering LUNA impossible (for example frozen pelvis with no access to uterosacral ligaments) or the finding of pelvic adhesions which did not appear to be due to endometriosis.<BR/>Location: Auckland, New Zealand.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups: <BR/>Group with endometriosis: <BR/>Treatment: LUNA with conservative surgery for endometriosis.<BR/>Control: conservative surgery for endometriosis.<BR/>Group without endometriosis:<BR/>Treatment: LUNA at laparoscopy.<BR/>Control: laparoscopy alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Changes in non-menstrual pelvic pain, dysmenorrhoea, deep dyspareunia and dyschezia were assessed primarily by whether there was a decrease in visual analog score for these types of pain of 50% or more from baseline; additionally whether there was a significantly different change in median visual analog score. The numbers requiring further surgery or starting a new medical treatment for pelvic pain and complications were also measured.<BR/>Adverse effects: no important intraoperative or postoperative complications occurred (specifically there were no cases of ureteric injury, intraoperative bleeding nor postoperative haematoma formation), other than 2 women who had urinary retention requiring catheterisation within 24 hours of the surgery (both in the endometriosis population not undergoing LUNA).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>137/200 agreed to participate; 14 excluded at laparoscopy; follow up at 12 months: 106/123 (86.2%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lichten-1987">
<CHAR_METHODS>
<P>Allocation concealment: inadequate.<BR/>Randomisation: randomised by last digit of medical case number on day of surgery. <BR/>Blinding: both participant and clinical psychologist, who recorded outcomes, were blinded.<BR/>Power Calculation: none stated.<BR/>Duration of trial: 12 mths<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women recruited: 39. 18 were excluded due to pathology (endometriosis, PID).<BR/>Number of women randomised: 21.<BR/>Number of women analysed: 21.<BR/>Drop-outs/withdrawals: none.<BR/>Inclusion criteria: women with severe dysmenorrhoea and no improvement with at least 2 NSAIDs and an oral contraceptive (30 and 50 ug of estrogen only) concurrently.<BR/>Exclusion criteria: history of psychotherapy, major abdominal procedures, drug abuse or demonstrable pelvic pathology.<BR/>Diagnosis: diagnostic laparoscopy. <BR/>Age: 18-34 yrs.<BR/>Location: USA.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: laparoscopic uterine nerve ablation.<BR/>Control: diagnostic laparoscopic surgery only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain was measured on a five point scale (0 = no pain to 4 = incapacitating pain unresponsive to potent pain relievers and the inability to function). Pain scores for each patient were reported preoperatively and at 3mths and 12mths. <BR/>Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sutton-2001">
<CHAR_METHODS>
<P>Allocation Concealment: unclear.<BR/>Randomisation: computer-generated randomisation sequence.<BR/>Blinding: double; participant and research nurse.<BR/>Power Calculation: done; sample for 90% power was 22 women in each group.<BR/>Duration of trial: women assessed at 3 and 6 months post operative (recruitment occurred over 33 months Feb.1995 to Nov. 1997).</P>
<P/>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 51.<BR/>Number of women analysed: 46 at 6 months.<BR/>Drop-outs/withdrawals: 5 (1 became pregnant and 4 were lost to follow up). However data points for to 14 women were missing for some analyses.<BR/>Inclusion criteria: women with history and physical or laparoscopic examination suggestive of endometriosis who had not received medical treatment for endometriosis within the last 6 months, and had not previously undergone surgical treatment of their disease.<BR/>Exclusion criteria: stage IV disease or any other pathology that may have been responsible in whole, or in part for their symptoms.<BR/>Diagnosis: at laparoscopy those with stage IV disease or other pathology were excluded.<BR/>Age: mean 28 (20 to 41).<BR/>Location: Surrey, UK.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: LUNA with laparoscopic treatment of all visible endometriosis.<BR/>Control: laparoscopic treatment of all visible endometriosis .<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dysmenorrhoea, measured by linear analogue scale (0 - 10) and pain scoring questionnaire.<BR/>Adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tjaden-1990">
<CHAR_METHODS>
<P>Allocation concealment: adequate.<BR/>Randomisation: centralised randomisation process, with sealed, opaque, sequentially numbered, identical envelopes. <BR/>Blinding: single; randomised participants were blinded.<BR/>Power Calculation: none stated.<BR/>Duration of trial: 6 months post-operative; however follow-up continued for a minimum of 42 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 8; also 18 women not randomised but followed up.<BR/>Number of women analysed: 26.<BR/>Drop-outs/withdrawals: none.<BR/>Inclusion criteria: women with moderate to severe dysmenorrhoea scheduled to undergo laparotomy for conservative resection of endometriosis.<BR/>Diagnosis: initial detailed history of pain and anatomical diagram for localisation of dysmenorrhoea, endometriosis confirmed at laparotomy.<BR/>Age: mean 30 yrs.<BR/>Location: USA.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: presacral neurectomy and resection of endometriosis.<BR/>Control: resection of endometriosis only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Relief of pain was reported as the number of women with pain relief in 3 locations.<BR/>Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data analysed pooled, and split into protocol (randomised) and non-protocol (non-randomised) groups. Study stopped by monitoring committee after 26 participants, as it was considered unethical not to provide those with midline dysmenorrhoea the pain relief that PSN exhibited.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vercellini-2003">
<CHAR_METHODS>
<P>Allocation concealment: adequate.<BR/>Randomisation: computer-generated randomisation in single blocks.<BR/>Blinding: used; patient and investigator blinded throughout the study.<BR/>Power Calculation: sample size based on assumption that dysmenorrhoea would reoccur in 30% of the controls and 10% of the treatment group. 72 patients were needed in each group to demonstrate a difference of 20% between control and treatment groups and to define statistical significance between the groups with an alpha of 0.05 and beta of .20.<BR/>Duration of trial: Sept. 1998 to Oct 2001. <BR/>Follow up : 6 and 12 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 180.<BR/>Number of women analysed: 116.<BR/>Drop-outs/withdrawals: 29 pregnant, 14 used oral contraception, 15 lost to follow-up, 6 miscellaneous reasons.<BR/>Inclusion criteria: Aged 18 to 40, undergoing first-line operative laparoscopy for symptomatic minimal to severe endometriosis who reported pelvic pain of more than 6 months duration.<BR/>Exclusion criteria: previous diagnosis of endometriosis, other diseases that might cause pelvic pain, treatment for endometriosis other than nonsteroid anti-inflammatory drugs up to 6 months before entry in the study, presence of vaginal endometriotic lesions, previous diagnosis of gastrointestinal, urologic and orthopedic diseases in which pain may radiate to the pelvic area, known psychiatric disturbances.<BR/>Age: 18-40. mean for each group not given.<BR/>Location: Milan, Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: conservative laparoscopic surgery with the addition of uterosacral ligament resection.<BR/>Control: conservative laparoscopic surgery.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dysmenorrhoea, measured by a 100 mm visual analog scale that ranged from "least possible pain" to "worst possible pain". Frequency was expressed as the number of episodes per each cycle for dysmenorrhoea and chronic pelvic pain.<BR/>Hospital anxiety and depression scale, sexual rating scale, SF 36.<BR/>Adverse effects: None attributable to pelvic denervation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Proportion of women satisfied with the treatment were similar.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yen-2001">
<CHAR_METHODS>
<P>Allocation concealment: inadequate.<BR/>Randomisation: Women with even hospital nos.(assigned on the day of surgery) were cases and those with odd hospital nos. were controls.<BR/>Blinding: double; patient and clinical psychologist.<BR/>Power Calculation: not stated.<BR/>Duration of trial: follow up at 1, 3 and 6 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 85.<BR/>Number of women analysed: 80 at 1, 3 and 6 months.<BR/>Drop-outs/withdrawals:5 (1 in each group had procedure converted to abdominal hysterectomy due to adhesions, 1 became pregnant and 2 were lost to follow-up).<BR/>Inclusion criteria: women with symptoms of uterine myomas, including dysmenorrhoea, menorrhagia, and bulk related symptoms, documented absence from school or work due to dysmenorrhoea and no response to OC or NSAIDS for at least two cycles.<BR/>Exclusion criteria: history of psychotherapy, major abdominal surgery or drug abuse.<BR/>Diagnosis: ultrasound.<BR/>Age: Control group mean 43.1, SD 5.1; <BR/>Treatment group mean 44.5, SD 4.4.<BR/>Location: Taipei, Taiwan.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: laparoscopic uterine nerve ablation with laparoscopic bipolar coagulation of uterine vessels (LBCUV).<BR/>Control: LBCUV.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dysmenorrhoea, improvement measured by analgesic use, and scale - completely resolved, significantly improved, slightly improved, unchanged or worsened. Pain data was reported the numbers of women slightly, significantly or completely improved.<BR/>Adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zullo-2003">
<CHAR_METHODS>
<P>Allocation concealment: unclear.<BR/>Randomisation: computer-generated randomisation in single blocks.<BR/>Blinding: double; participant and investigator blinded throughout the study.<BR/>Power Calculation: sample size based on assumption that dysmenorrhoea would resolve in 50% controls, 58 women were needed in each group to demonstrate a difference of 25% between control and experimental groups and to define statistical significance between the groups with an alpha of 0.05 and beta of 0.20.<BR/>Duration of trial: Sept. 1998 to Oct 2001.<BR/>Follow up: 6 and 12 post operative.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number of women randomised: 141.<BR/>Number of women analysed: 126.<BR/>Drop-outs/withdrawals: 7 due to the presence of other gynecological diseases, 5 because endometriosis was not confirmed, 3 failed to undergo postoperative subjective evaluation of dysmenorrhea. <BR/>Inclusion criteria: sexually active women of fertile age with severe dysmenorrhea for more than six months who were unresponsive to medical treatment and had a clinical and/or ultrasonographic diagnosis of endometriosis.<BR/>Exclusion criteria: pregnancy, women without midline dysmenorrhoea, breastfeeding, use of an intrauterine device, major medical diseases, psychiatric disorders, neurologic alterations of the lumbar-sacral tract, previous pelvic surgery, history of severe abdominal or pelvic infection, presence of other gynaecologic diseases, body mass index of &gt;30 kg/m2, history of alcohol or other drug abuse.<BR/>Age: control group mean 31.8, SD 4.9; PSN surgery group mean 30.1, SD 3.7<BR/>Location: Catanzaro, Rome and Messina, Italy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: laparoscopic presacral neurectomy with conservative surgery for endometriosis.<BR/>Control: conservative surgery for endometriosis.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dysmenorrhoea, measured by a 100 mm visual analog scale that ranged from "least possible pain" to "worst possible pain". Frequency was expressed as the number of episodes per each cycle for dysmenorrhea and chronic pelvic pain.<BR/>Adverse effects: Significant bleeding from middle sacral vein in 1 woman in treatment group, initial urinary retention in 2 women in treatment group; significant increase in operating time in treatment group (P value &lt; 0.05).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>SD = standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Garcia-Leon-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised controlled trial comparing LPSN and LUNA (Spanish). Patients had chronic pelvic pain which may or may not have included dysmenorrhoea. Approximately 60 to 80% of women in each treatment group had dysmenorrhoea at baseline. Unable to separate out data for women with dysmenorrhoea at baseline or at end of treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutton-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double blind, randomised trial, interventions were laparoscopic uterine nerve transection combined with vaporisation of endometriosis implants versus no treatment (expectant management only). Therefore data on pain relief as a result of LUNA could not be distinguished from pain relief as a result of the laser vaporisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Birmingham-trial">
<CHAR_STUDY_NAME>
<P>A randomised controlled trial to assess the efficacy of laparoscopic uterosacral nerve ablation (LUNA) in the treatment of chronic pelvic pain.</P>
<P>A multi-centre, prospective randomised-controlled trial with double blind assessment of outcomes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>New patients presenting to the gynaecology outpatient clinic with pelvic pain (cyclical or non-cyclical) and/or dyspareunia, and requiring diagnostic laparoscopy for evaluation of these conditions, will be invited to participate.</P>
<P>Inclusion criteria: pelvic pain for longer than 6 months duration; pain located within the true pelvis or between and below the anterior iliac crests; associated functional disability; lack of response to medical treatment; diagnostic laparoscopy planned.<BR/>Exclusion criteria: previous LUNA; mild, moderate and severe endometriosis (American Fertility Society Score &gt;5); previous surgery for endometriosis; previous surgery for pelvic inflammatory disease; previous hysterectomy; adnexal pathology</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Diagnostic laparoscopy plus uterosacral nerve ablation (experimental group) or laparoscopy without pelvic denervation (control group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Postal questionnaires including visual analogue scale for pain (primary outcome), an index of sexual satisfaction and the EuroQol 5D-EQ instrument (secondary outcomes) will be administered at 3, 6, 12, 24 and 36 months and 5 and 10 years. The primary assessment of the effectiveness of LUNA will be from comparison of outcomes at the one-year follow-up, although the short-term and longer-term risks and benefits of LUNA will also be evaluated.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Date ISRCTN assigned: Oct 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>The LUNA Trial Collaboration, Dr Pallavi Latthe.<BR/>Email: pallavi.latthe@bwhct.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ISRCTN41196151</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Candiani-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chen-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Lichten-1987">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sutton-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tjaden-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vercellini-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Yen-2001">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zullo-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>LUNA versus control</NAME>
<DICH_OUTCOME CHI2="15.591023932469202" CI_END="1.9910769006649034" CI_START="0.6621666119503303" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1482267395622885" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" I2="74.3442123023763" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.29908803395481454" LOG_CI_START="-0.17903272121502214" LOG_EFFECT_SIZE="0.060027656369896175" METHOD="MH" NO="1" P_CHI2="0.003620043941347739" P_Q="0.0" P_Z="0.6226178049932691" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="134" WEIGHT="100.0" Z="0.49214364065643146">
<NAME>Pain relief - up to 6 months</NAME>
<GROUP_LABEL_1>LUNA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LUNA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.272906887406133" CI_END="3.686326297226245" CI_START="0.5551256144823868" DF="1.0" EFFECT_SIZE="1.4305153445280834" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="90.26565692690225" ID="CMP-001.01.01" LOG_CI_END="0.5665937744025624" LOG_CI_START="-0.25560873308660875" LOG_EFFECT_SIZE="0.1554925206579768" NO="1" P_CHI2="0.0013499930454758946" P_Z="0.4584962602969791" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="38" WEIGHT="29.649506279143747" Z="0.7413252515749565">
<NAME>Primary dysmenorrhoea</NAME>
<DICH_DATA CI_END="1.446566121792387" CI_START="0.0787425118589553" EFFECT_SIZE="0.3375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.16033828981480222" LOG_CI_START="-1.1037907354807146" LOG_EFFECT_SIZE="-0.4717262228329563" ORDER="13262" O_E="0.0" SE="0.7425556469981822" STUDY_ID="STD-Johnson-2004" TOTAL_1="19" TOTAL_2="28" VAR="0.5513888888888889" WEIGHT="28.842600202062243"/>
<DICH_DATA CI_END="530.2934938656107" CI_START="3.0930984803213137" EFFECT_SIZE="40.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="2.7245162988221323" LOG_CI_START="0.4903937476072051" LOG_EFFECT_SIZE="1.6074550232146685" ORDER="13263" O_E="0.0" SE="1.3123346456686351" STUDY_ID="STD-Lichten-1987" TOTAL_1="11" TOTAL_2="10" VAR="1.7222222222222223" WEIGHT="0.8069060770815032"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.32187130351318" CI_END="2.02234809197184" CI_START="0.5238296723840965" DF="2.0" EFFECT_SIZE="1.029255040533789" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="60" I2="62.41923402620203" ID="CMP-001.01.02" LOG_CI_END="0.3058559096187533" LOG_CI_START="-0.2808099045597154" LOG_EFFECT_SIZE="0.012523002529518965" NO="2" P_CHI2="0.06988295702519953" P_Z="0.9333148265782909" STUDIES="3" TAU2="0.0" TOTAL_1="94" TOTAL_2="96" WEIGHT="70.35049372085625" Z="0.08367501000729685">
<NAME>Secondary dysmenorrhoea</NAME>
<DICH_DATA CI_END="1.447470264130272" CI_START="0.14273976838624636" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.16060965063312754" LOG_CI_START="-0.84545501227754" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="13264" O_E="0.0" SE="0.5909673630941257" STUDY_ID="STD-Johnson-2004" TOTAL_1="30" TOTAL_2="31" VAR="0.3492424242424242" WEIGHT="36.667928617539786"/>
<DICH_DATA CI_END="2.768758683027655" CI_START="0.2277637416492549" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.4422851055482134" LOG_CI_START="-0.6425154113147491" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="13265" O_E="0.0" SE="0.6372171934544665" STUDY_ID="STD-Sutton-2001" TOTAL_1="26" TOTAL_2="23" VAR="0.40604575163398693" WEIGHT="23.51554853208952"/>
<DICH_DATA CI_END="14.439525194857598" CI_START="0.9205358566207017" EFFECT_SIZE="3.6458333333333335" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="1.1595529128566437" LOG_CI_START="-0.035959290235229355" LOG_EFFECT_SIZE="0.5617968113107072" ORDER="13266" O_E="0.0" SE="0.7022497859770139" STUDY_ID="STD-Yen-2001" TOTAL_1="38" TOTAL_2="42" VAR="0.49315476190476193" WEIGHT="10.16701657122694"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.847325567819006" CI_END="1.9862353433194175" CI_START="0.7197037103839014" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1956173912596901" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="72" I2="66.09144789571089" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2980307055136184" LOG_CI_START="-0.1428462583308474" LOG_EFFECT_SIZE="0.0775922235913855" METHOD="MH" NO="2" P_CHI2="0.03139120211490121" P_Q="0.0" P_Z="0.49026434132698404" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="147" WEIGHT="100.0" Z="0.6898884550164219">
<NAME>Pain relief - up to 12 months</NAME>
<GROUP_LABEL_1>LUNA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LUNA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6929264743696596" CI_END="21.030352381805972" CI_START="1.7819582582957625" DF="1.0" EFFECT_SIZE="6.1216999356085" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.3228465497282476" LOG_CI_START="0.2508975266345614" LOG_EFFECT_SIZE="0.7868720381814044" NO="1" P_CHI2="0.4051711617438917" P_Z="0.004009010739747453" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="38" WEIGHT="7.90582944096221" Z="2.877451860212928">
<NAME>Primary dysmenorrhoea</NAME>
<DICH_DATA CI_END="17.631187701580775" CI_START="1.0799795587419432" EFFECT_SIZE="4.363636363636363" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="1.2462815689566553" LOG_CI_START="0.03341553547806899" LOG_EFFECT_SIZE="0.6398485522173621" ORDER="13267" O_E="0.0" SE="0.712443511849015" STUDY_ID="STD-Johnson-2004" TOTAL_1="19" TOTAL_2="28" VAR="0.5075757575757576" WEIGHT="6.869027168279679"/>
<DICH_DATA CI_END="377.40432900841205" CI_START="0.8366241133475179" EFFECT_SIZE="17.76923076923077" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.5768068774231967" LOG_CI_START="-0.07746962225258136" LOG_EFFECT_SIZE="1.2496686275853075" ORDER="13268" O_E="0.0" SE="1.5591351547901264" STUDY_ID="STD-Lichten-1987" TOTAL_1="11" TOTAL_2="10" VAR="2.430902430902431" WEIGHT="1.0368022726825306"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.47632955862966053" CI_END="1.3948048556583847" CI_START="0.4281052763216042" DF="1.0" EFFECT_SIZE="0.7727375480370733" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="68" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.14451345059236156" LOG_CI_START="-0.3684494195302401" LOG_EFFECT_SIZE="-0.11196798446893923" NO="2" P_CHI2="0.4900896352714119" P_Z="0.3922024648037571" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="109" WEIGHT="92.09417055903779" Z="0.8556300261194743">
<NAME>Secondary dysmenorrhoea</NAME>
<DICH_DATA CI_END="1.6980082915418298" CI_START="0.18033300613100606" EFFECT_SIZE="0.5533596837944664" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2299398066158674" LOG_CI_START="-0.7439247776110272" LOG_EFFECT_SIZE="-0.25699248549757986" ORDER="13269" O_E="0.0" SE="0.5720528774823171" STUDY_ID="STD-Johnson-2004" TOTAL_1="30" TOTAL_2="31" VAR="0.32724449463579897" WEIGHT="30.43204249553415"/>
<DICH_DATA CI_END="1.770561501806812" CI_START="0.43837680609507407" EFFECT_SIZE="0.8810068649885584" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="57" LOG_CI_END="0.24811101690685272" LOG_CI_START="-0.358152431830695" LOG_EFFECT_SIZE="-0.055020707461921135" ORDER="13270" O_E="0.0" SE="0.35612215084090715" STUDY_ID="STD-Vercellini-2003" TOTAL_1="78" TOTAL_2="78" VAR="0.12682298631955383" WEIGHT="61.66212806350364"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8019805384420144" CI_START="0.38847269712949983" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8366721221263665" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2557500962474373" LOG_CI_START="-0.41063949913507736" LOG_EFFECT_SIZE="-0.07744470144382007" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.648709428273245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="57" WEIGHT="100.0" Z="0.4555558090195454">
<NAME>Pain relief up to 36 months</NAME>
<GROUP_LABEL_1>LUNA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LUNA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8019805384420144" CI_START="0.38847269712949983" DF="0.0" EFFECT_SIZE="0.8366721221263665" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2557500962474373" LOG_CI_START="-0.41063949913507736" LOG_EFFECT_SIZE="-0.07744470144382007" NO="2" P_CHI2="1.0" P_Z="0.648709428273245" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="57" WEIGHT="100.0" Z="0.4555558090195454">
<NAME>Secondary dysmenorrhoea</NAME>
<DICH_DATA CI_END="1.8019805384420144" CI_START="0.38847269712949983" EFFECT_SIZE="0.8366721221263665" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.2557500962474373" LOG_CI_START="-0.41063949913507736" LOG_EFFECT_SIZE="-0.07744470144382007" ORDER="13271" O_E="-1.1637931034482776" SE="0.3914405470093867" STUDY_ID="STD-Vercellini-2003" TOTAL_1="59" TOTAL_2="57" VAR="6.526320245049888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>PSN versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.092560220374512" CI_START="1.8442782051115514" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.5230263157894735" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.0450317951353003" LOG_CI_START="0.26582643397975514" LOG_EFFECT_SIZE="0.6554291145575277" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="9.763653389517049E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.00000000000001" Z="3.2972500524038253">
<NAME>Pain relief - up to 6 months</NAME>
<GROUP_LABEL_1>PSN</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PSN</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.092560220374512" CI_START="1.8442782051115514" DF="0.0" EFFECT_SIZE="4.5230263157894735" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.0450317951353003" LOG_CI_START="0.26582643397975514" LOG_EFFECT_SIZE="0.6554291145575277" NO="2" P_CHI2="1.0" P_Z="9.763653389517049E-4" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.00000000000001" Z="3.2972500524038253">
<NAME>PSN with surgical treatment of endometriosis vs surgical treatment of endometriosis only</NAME>
<DICH_DATA CI_END="11.092560220374512" CI_START="1.8442782051115514" EFFECT_SIZE="4.5230263157894735" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" LOG_CI_END="1.0450317951353003" LOG_CI_START="0.26582643397975514" LOG_EFFECT_SIZE="0.6554291145575277" ORDER="13272" O_E="0.0" SE="0.45770908627151197" STUDY_ID="STD-Zullo-2003" TOTAL_1="63" TOTAL_2="63" VAR="0.2094976076555024" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9408554195733603" CI_END="6.2147869386642585" CI_START="1.5882846936594999" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.1417910447761197" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="63" I2="48.476326988858325" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.7934262443294695" LOG_CI_START="0.20092835061225198" LOG_EFFECT_SIZE="0.4971772974708607" METHOD="MH" NO="2" P_CHI2="0.1635759608410129" P_Q="0.0" P_Z="0.0010043939451717151" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="99" WEIGHT="100.0" Z="3.289293033129064">
<NAME>Pain relief - up to 12 months</NAME>
<GROUP_LABEL_1>PSN</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PSN</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9408554195733603" CI_END="6.2147869386642585" CI_START="1.5882846936594999" DF="1.0" EFFECT_SIZE="3.1417910447761197" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="63" I2="48.476326988858325" ID="CMP-002.02.02" LOG_CI_END="0.7934262443294695" LOG_CI_START="0.20092835061225198" LOG_EFFECT_SIZE="0.4971772974708607" NO="2" P_CHI2="0.1635759608410129" P_Z="0.0010043939451717151" STUDIES="2" TAU2="0.0" TOTAL_1="98" TOTAL_2="99" WEIGHT="100.0" Z="3.289293033129064">
<NAME>PSN with surgical treatment of endometriosis vs surgical treatment of endometriosis only</NAME>
<DICH_DATA CI_END="5.130947132192827" CI_START="0.5058869143398008" EFFECT_SIZE="1.6111111111111112" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" LOG_CI_END="0.7101975398326967" LOG_CI_START="-0.29594655424139654" LOG_EFFECT_SIZE="0.20712549279565004" ORDER="13273" O_E="0.0" SE="0.5910140213527124" STUDY_ID="STD-Candiani-1992" TOTAL_1="35" TOTAL_2="36" VAR="0.34929757343550444" WEIGHT="47.014925373134325"/>
<DICH_DATA CI_END="10.679652302598743" CI_START="1.8961291459903105" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="36" LOG_CI_END="1.0285571135988283" LOG_CI_START="0.2778679139518591" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="13274" O_E="0.0" SE="0.4409585518440984" STUDY_ID="STD-Zullo-2003" TOTAL_1="63" TOTAL_2="63" VAR="0.19444444444444442" WEIGHT="52.985074626865675"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="42.147507624769865" CI_START="5.039541039891343" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="14.574089831072165" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.6247718978975816" LOG_CI_START="0.7023909862632398" LOG_EFFECT_SIZE="1.1635814420804107" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="7.615156413511413E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="4.944980302152806">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="42.147507624769865" CI_START="5.039541039891343" DF="0.0" EFFECT_SIZE="14.574089831072165" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.6247718978975816" LOG_CI_START="0.7023909862632398" LOG_EFFECT_SIZE="1.1635814420804107" NO="2" P_CHI2="1.0" P_Z="7.615156413511413E-7" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="4.944980302152806">
<NAME>PSN with surgical treatment of endometriosis vs surgical treatment of endometriosis only</NAME>
<DICH_DATA CI_END="42.14750762476989" CI_START="5.0395410398913425" EFFECT_SIZE="14.574089831072165" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="1.6247718978975818" LOG_CI_START="0.7023909862632397" LOG_EFFECT_SIZE="1.1635814420804107" ORDER="13275" O_E="9.126760563380282" SE="0.5418111133531623" STUDY_ID="STD-Candiani-1992" TOTAL_1="35" TOTAL_2="36" VAR="3.406466970839119" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>LUNA versus LPSN</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.612692145408905" CI_START="0.17010976407053335" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.41708823964436803" LOG_CI_START="-0.7692707577557305" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5606779063605869" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.5818348855579207">
<NAME>Pain relief - up to 6 months</NAME>
<GROUP_LABEL_1>LUNA</GROUP_LABEL_1>
<GROUP_LABEL_2>LPSN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LPSN</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LUNA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.612692145408905" CI_START="0.17010976407053335" DF="0.0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.41708823964436803" LOG_CI_START="-0.7692707577557305" LOG_EFFECT_SIZE="-0.17609125905568127" NO="1" P_CHI2="1.0" P_Z="0.5606779063605869" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.5818348855579207">
<NAME>Primary dysmenorrhoea</NAME>
<DICH_DATA CI_END="2.612692145408905" CI_START="0.17010976407053335" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.41708823964436803" LOG_CI_START="-0.7692707577557305" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="13276" O_E="0.0" SE="0.6968731476445666" STUDY_ID="STD-Chen-1996" TOTAL_1="35" TOTAL_2="33" VAR="0.48563218390804597" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.3173783998302754" CI_START="0.03268590342379688" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.10185185185185185" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.4984226338311177" LOG_CI_START="-1.4856395068263317" LOG_EFFECT_SIZE="-0.9920310703287247" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="8.180705275061349E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="3.9390436338266435">
<NAME>Pain relief - up to 12 months</NAME>
<GROUP_LABEL_1>LUNA</GROUP_LABEL_1>
<GROUP_LABEL_2>LPSN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours LPSN</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LUNA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3173783998302754" CI_START="0.03268590342379688" DF="0.0" EFFECT_SIZE="0.10185185185185185" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.4984226338311177" LOG_CI_START="-1.4856395068263317" LOG_EFFECT_SIZE="-0.9920310703287247" NO="1" P_CHI2="1.0" P_Z="8.180705275061349E-5" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="3.9390436338266435">
<NAME>Primary dysmenorrhoea</NAME>
<DICH_DATA CI_END="0.3173783998302754" CI_START="0.03268590342379688" EFFECT_SIZE="0.10185185185185185" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.4984226338311177" LOG_CI_START="-1.4856395068263317" LOG_EFFECT_SIZE="-0.9920310703287247" ORDER="13277" O_E="0.0" SE="0.5798960779997234" STUDY_ID="STD-Chen-1996" TOTAL_1="35" TOTAL_2="33" VAR="0.3362794612794613" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.06181823952483146" CI_START="0.009286638404448348" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.02396004251387478" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-1.2088833670426564" LOG_CI_START="-2.0321414643270668" LOG_EFFECT_SIZE="-1.6205124156848614" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.2000019894075601E-14" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="7.716039433366353">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.06181823952483146" CI_START="0.009286638404448348" DF="0.0" EFFECT_SIZE="0.02396004251387478" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="31" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="-1.2088833670426564" LOG_CI_START="-2.0321414643270668" LOG_EFFECT_SIZE="-1.6205124156848614" NO="3" P_CHI2="1.0" P_Z="1.2000019894075601E-14" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="100.0" Z="7.716039433366353">
<NAME>Primary dysmenorrhoea</NAME>
<DICH_DATA CI_END="0.06181823952483146" CI_START="0.009286638404448357" EFFECT_SIZE="0.02396004251387478" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="31" LOG_CI_END="-1.2088833670426564" LOG_CI_START="-2.032141464327066" LOG_EFFECT_SIZE="-1.6205124156848614" ORDER="13278" O_E="-15.955882352941176" SE="0.48358588153816773" STUDY_ID="STD-Chen-1996" TOTAL_1="35" TOTAL_2="33" VAR="4.276148453235551" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Sensory afferent nerve supply of the female pelvic organs. C = afferent nerve supply of cervix (illustrated on right side of diagram); O = afferent nerve supply of ovary (illustrated on left side of diagram); U = afferent nerve supply of uterus (illustrated on right side of diagram); P = parasympathetic nerve; S = sympathetic nerve. Copyright approval for reproduction of this figure has been kindly granted by Blackwell Science, publisher of Gynaecological Endoscopy (Johnson 2000).</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>figures</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY/>
<FEEDBACK_REPLY>
<P>:</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>